U.S. patent application number 16/709147 was filed with the patent office on 2020-04-02 for delivery of packaged rna to mammalian cells.
The applicant listed for this patent is The USA, as represented by the Secretary, Dept. of Health and Human Services. Invention is credited to Deb K. Chatterjee, Stanislaw J. Kaczmarczyk.
Application Number | 20200102545 16/709147 |
Document ID | / |
Family ID | 47998556 |
Filed Date | 2020-04-02 |
![](/patent/app/20200102545/US20200102545A1-20200402-D00001.png)
![](/patent/app/20200102545/US20200102545A1-20200402-D00002.png)
![](/patent/app/20200102545/US20200102545A1-20200402-D00003.png)
![](/patent/app/20200102545/US20200102545A1-20200402-D00004.png)
![](/patent/app/20200102545/US20200102545A1-20200402-D00005.png)
![](/patent/app/20200102545/US20200102545A1-20200402-D00006.png)
![](/patent/app/20200102545/US20200102545A1-20200402-D00007.png)
![](/patent/app/20200102545/US20200102545A1-20200402-D00008.png)
![](/patent/app/20200102545/US20200102545A1-20200402-D00009.png)
![](/patent/app/20200102545/US20200102545A1-20200402-D00010.png)
![](/patent/app/20200102545/US20200102545A1-20200402-D00011.png)
View All Diagrams
United States Patent
Application |
20200102545 |
Kind Code |
A1 |
Kaczmarczyk; Stanislaw J. ;
et al. |
April 2, 2020 |
DELIVERY OF PACKAGED RNA TO MAMMALIAN CELLS
Abstract
Described herein are compositions relating to alphavirus-based
virus-like particles (VLPs) and methods for making and using the
described VLPs. The described compositions include VLPs and vectors
and cells used to produce the VLPs. Also included are related
methods to produce the VLPs, to transduce cells using the VLPs, and
to produce a protein or polynucleotide of interest in a target cell
using the VLPs. Also described are alphavirus-based replicons that
allow for expression of proteins or polynucleotides of interest in
a target cell without a cytopathic effect.
Inventors: |
Kaczmarczyk; Stanislaw J.;
(Frederick, MD) ; Chatterjee; Deb K.; (Potomac,
MD) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
The USA, as represented by the Secretary, Dept. of Health and Human
Services |
Bethesda |
MD |
US |
|
|
Family ID: |
47998556 |
Appl. No.: |
16/709147 |
Filed: |
December 10, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15190992 |
Jun 23, 2016 |
10538743 |
|
|
16709147 |
|
|
|
|
14388441 |
Sep 26, 2014 |
9506041 |
|
|
PCT/US2013/031876 |
Mar 15, 2013 |
|
|
|
15190992 |
|
|
|
|
61615687 |
Mar 26, 2012 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 35/76 20130101;
C12N 2770/36152 20130101; C12N 2310/141 20130101; C12N 2800/24
20130101; A61K 38/1774 20130101; C12N 15/86 20130101; C12N 15/113
20130101; C12N 2770/36123 20130101; C12N 2740/11022 20130101; C12N
2740/11023 20130101; C12N 2740/13022 20130101; C12N 2770/36143
20130101; C12N 2810/6081 20130101; A61K 48/0066 20130101; C12N
2320/32 20130101; C12N 2740/11042 20130101; C12N 2740/11051
20130101; C12N 2740/13051 20130101; C12N 2310/11 20130101; C12N
2770/36145 20130101; C12N 7/00 20130101 |
International
Class: |
C12N 7/00 20060101
C12N007/00; C12N 15/86 20060101 C12N015/86; A61K 35/76 20060101
A61K035/76; A61K 38/17 20060101 A61K038/17; A61K 48/00 20060101
A61K048/00; C12N 15/113 20060101 C12N015/113 |
Claims
1. A virus like particle (VLP) consisting of: a. an alphavirus
replicon isolated from Sindbis virus or Venezuelan equine
encephalitis virus comprising a recombinant polynucleotide
comprising a sequence encoding Sindbis virus or Venezuelan equine
encephalitis virus nonstructural proteins NSP1, NSP2, NSP3, and
NSP4; and a retroviral packaging signal isolated from Rous sarcoma
virus, b. a retroviral gag protein encoded by a polynucleotide
comprising a genomic sequence of a Rous sarcoma virus, and c. a
fusogenic envelope protein, wherein the VLP does not contain an
alphavirus structural protein gene.
2. The VLP of claim 1, wherein the fusogenic envelope protein is
encoded by a polynucleotide comprising a genomic sequence encoding
an envelope protein selected from the group consisting of
haemagglutinin, Rous sarcoma virus fusion protein, an E protein of
tick borne encephalitis virus and dengue fever virus, the E1
protein of Semliki Forest virus, baculovirus gp64, VSV-EnvA, and
VSV-G protein.
3. The VLP of claim 1, wherein the VLP is not cytopathic to a
eukaryotic cell.
4. The VLP of claim 1, wherein the alphavirus replicon comprises a
promoter of a virus RNA-dependent RNA polymerase, wherein said
promoter is linked to the recombinant polynucleotide.
5. The VLP of claim 1, wherein the recombinant polynucleotide
encodes an antisense RNA, that knocks down expression of a gene in
the eukaryotic cell.
6. The VLP of claim 1, wherein the recombinant polynucleotide
encodes a shRNA or a miRNA, wherein the shRNA or miRNA knocks down
expression of a gene in the eukaryotic cell.
7. A method of producing a VLP comprising: a. co-transforming a
eukaryotic cell with: i. a first vector comprising a polynucleotide
sequence encoding the alphavirus replicon, wherein the alphavirus
replicon includes the polynucleotide of interest, ii. a second
vector comprising a polynucleotide sequence encoding the retroviral
Rous gag protein, and iii. a third vector comprising a
polynucleotide sequence encoding the fusogenic envelope protein; b.
culturing the co-transformed cell under conditions suitable to
cause each vector to produce its encoded product, thereby producing
the VLP; and c. isolating the VLP from the cell; wherein neither
the vectors nor the cell contain any alphavirus structural protein
genes.
8. A method of treating or preventing a disease or a disorder in a
subject, comprising administering to a subject the VLP of claim
1.
9. The method of claim 8, wherein the vector comprising the
polynucleotide sequence encoding the alphavirus replicon is
pDest472-VEE or pDest472-VEE-MCS.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The application is a divisional of U.S. patent application
Ser. No. 15/190,992, filed Jun. 23, 2016, which is a continuation
of U.S. patent application Ser. No. 14/388,441, filed Sep. 26,
2014, now U.S. Pat. No. 9,506,041, which claims the benefit of
application number PCT/US2013/031876, filed Mar. 15, 2013, which
claims the benefit of U.S. Provisional Application No. 61/615,687
filed Mar. 26, 2012, which is hereby incorporated by reference in
its entirety.
TECHNICAL FIELD
[0002] The invention described herein relates to delivering and
transcribing recombinant polynucleotides to mammalian cells using
replication-defective virus-like particles.
BACKGROUND
[0003] Alphaviruses belong to the group IV Togaviridae family of
viruses. The alphaviruses are small, spherical, enveloped viruses
with a genome of a single positive sense strand RNA. The total
genome length ranges between 11,000 and 12,000 nucleotides, and has
a 5' cap, and 3' poly-A tail. The four non-structural protein genes
(NSP genes) are encoded in the 5' two-thirds of the genome, while
the three structural proteins are translated from a subgenomic mRNA
colinear with the 3' one-third of the genome.
[0004] There are two open reading frames (ORFs) in the alphavirus
genome, non-structural and structural. The first includes NSP genes
and encodes proteins (nsP1-nsP4) necessary for transcription and
replication of viral RNA. The second encodes three structural
proteins: the core nucleocapsid protein C, and the envelope
proteins P62 and E1 that associate as a heterodimer. The viral
membrane-anchored surface glycoproteins are responsible for
receptor recognition and entry into target cells through membrane
fusion.
[0005] The Sindbis (and VEEV) virus is an alphavirus whose genome
comprises a positive mRNA strand of 11703 nucleotides. This virus
infects a variety of vertebrate hosts. The genome of Sindbis virus
encodes nonstructural (NS, replicon) and structural proteins
(capsid and pH dependent fusogenic envelope) that are directly
translated in the cytoplasm of the host cell. The alphaviruses also
include Aura virus, Babanki virus, Barmah Forest virus, Bebaru
virus, Cabassou virus, Chikungunya virus, Eastern equine
encephalitis virus, Everglades virus, Fort Morgan virus, Getah
virus, Highlands J virus, Kyzylagach virus, Mayaro virus, Me Tri
virus, Middelburg virus, Mosso das Pedras virus, Mucambo virus,
Ndumu virus, O'nyong-nyong virus, Pixuna virus, Rio Negro virus,
Ross River virus, Salmon pancreas disease virus, Semliki Forest
virus, Southern elephant seal virus, Tonate virus, Trocara virus,
Una virus, Venezuelan equine encephalitis virus, Western equine
encephalitis virus, and Whataroa virus.
[0006] Infection of host cell with an alphavirus results in
cytotoxicity culminating with apoptosis, This is mostly due to
both: expression of alphavirus genomic RNA in large quantities
triggering antiviral state in host cells and direct interaction of
alphaviral non-structural proteins ( NSP2 of SIN or NC of VEEV)
with cellular mRNA synthesis or translational shut-off causing
cytophathic effect (CPE) on host cell host cell. A natural Sindbis
virus variant containing a point mutation in one of the
nonstructural proteins, NSP2 (at position 726) demonstrated
sustained and noncytopathic growth in infected cells although the
viral titer recovered from infected cells was substantially reduced
(Frolov, I. et al., J. Virol. 3845-65 (May, 1999)).
[0007] Alphaviruses are of interest to gene therapy researchers.
Ross River virus, Sindbis virus, Semliki Forest virus (SFV), and
Venezuelan equine encephalitis virus (VEEV) have all been used to
develop vectors for gene delivery. Pseudotyped viruses may be
formed by combining alphaviral envelopes glycoproteins and
retroviral capsids. Alphaviral envelope glycoproteins pseudotyped
retroviruses or lentiviruses are able to integrate the genes that
they carry into the potential host cells. The pseudotyped
alphaviruses are recognized and infected by the alphaviral envelope
proteins E2 and E1. Stable integration of viral genes is mediated
by retroviral interiors of these vectors.
[0008] There are limitations to the use of alphaviruses in the
field of gene therapy due to their lack of specificity of
targeting. However, through the introduction of variable antibody
domains in a non-conserved loop in the structure of E2, specific
populations of cells have been targeted. Furthermore, the use of
whole alphaviruses for gene therapy is of limited efficacy both
because several internal alphaviral proteins are involved in the
induction of apoptosis upon infection and also because the
alphaviral capsid mediates only the transient introduction of mRNA
into host cells. Neither of these limitations extends to alphaviral
envelope pseudotypes of retroviruses or lentiviruses.
SUMMARY
[0009] One aspect of the description is a virus-like particle (VLP)
comprising an alphavirus replicon, wherein the alphavirus replicon
comprises a recombinant polynucleotide, a retroviral gag protein, a
fusogenic envelope protein, in which the VLP does not contain an
alphavirus structural protein gene. The alphavirus replicon may be
derived from Sindbis virus or VEEV nonstructural proteins NSP1,
NSP2, NSP3, and NSP4, and a retroviral packaging signal. The
retroviral gag protein may be derived from Rous sarcoma virus or
murine leukemia virus. The fusogenic envelope protein is selected
from the group consisting of haemagglutinin, Rous sarcoma virus
(RSV) fusion protein, an E protein of tick borne encephalitis virus
and dengue fever virus, the E1 protein of SFV, baculovirus gp64,
and Vesicular stomatitis (Indiana) virus-G (VSV-G) protein,
preferably a glycoprotein, or fragment or derivative thereof, more
preferably from a RNA virus or a retrovirus, or fragment or
derivative thereof, most preferably VSV-G or EnvA, or an alteration
of VSV-G. The VLP described herein may be capable of binding to a
eukaryotic cell, preferably a human cell. The binding of the VLP
may be specific to a target cell. The VLP described herein
preferably replicates in the target cell. In some embodiments the
VLP described herein is not cytopathic to the cell. The recombinant
polynucleotide of the VLP may comprise a miRNA, shRNA or an
antisense RNA, preferably a shRNA or antisense RNA that knocks down
expression of a gene in the cell. The recombinant polynucleotide of
the VLP may comprise an RNA encoding a protein that can be
expressed by the cell.
[0010] Another embodiment of the description is a method of
producing the VLP described herein, comprising the steps of
co-transforming a eukaryotic cell with a first vector comprising a
polynucleotide sequence encoding the alphavirus replicon, wherein
the alphavirus replicon includes the polynucleotide of interest, a
second vector comprising a polynucleotide sequence encoding the
retroviral gag protein, and a third vector comprising a
polynucleotide sequence encoding the fusogenic envelope protein;
culturing the co-transformed cell under conditions suitable to
cause each vector to produce its encoded product, thereby producing
the VLP, and isolating the VLP from the cell, wherein neither the
vectors nor the cell contain any alphavirus structural protein
genes.
[0011] Another embodiment of the description is kit comprising a
first vector comprising a polynucleotide sequence encoding an
alphavirus replicon, wherein the alphavirus replicon includes the
polynucleotide of interest; a second vector comprising a
polynucleotide sequence encoding the retroviral gag protein; and a
third vector comprising a polynucleotide sequence encoding the
fusogenic envelope protein, such as VSV-G. In some embodiments, the
vectors provided with the kits do not include alphavirus structural
protein genes. Alternatively, in some embodiments one or more of
the alphavirus replicon, retroviral gag protein and fusogenic
envelope protein may be encoded by the same vector.
[0012] Another embodiment of the description is a method of
expressing the recombinant polynucleotide in a eukaryotic cell
comprising treating a cell with the VLP described herein.
[0013] Another embodiment of the description is a method of
delivering the recombinant polynucleotide described herein to a
subject, comprising administering to said subject the VLP described
herein.
[0014] Another embodiment of the description is a method of
treating or preventing a disease or a disorder in a subject,
comprising administering to a subject the VLP described herein.
Preferably, expression of the gene of interest supplements
deficient expression of an endogenous gene by said subject.
[0015] Another embodiment of the description is a pharmaceutical
composition comprising the VLP described herein.
[0016] Another embodiment of the description is a eukaryotic cell
produced by treating the cell with a VLP described herein.
[0017] To produce VLPS of this sort several components may be
produced by transfecting or nucleofecting one or more vectors
encoding these components into a cell line for in vitro production.
In some embodiments, these components are encoded by separate
vectors to reduce the likelihood that the resulting VLP will be
replication competent. For example, a multi-vector system may be
used where one vector encodes the genetic material, such as an
alphavirus-based RNA polynucleotide, to be packaged by the VLP;
another encodes the structural proteins of the VLP, such a gag
protein; and another vector encodes a fusion protein, such as
VSV-G, to facilitate fusion of the VLP to the membrane of a target
cell. The alphavirus-based RNA polynucleotide can be derived from
any alphavirus. In some embodiments, the RNA polynucleotide is
derived from Sindbis virus and encodes Sindbis virus nonstructural
protein. In some embodiments, the RNA polynucleotide is derived
from Venezuelan equine encephalitis virus (VEEV) and encodes VEEV
nonstructural proteins. However, other alphavirus nonstructural
proteins may suffice for the RNA construct described herein.
Suitable alphaviruses include Aura virus, Babanki virus, Barmah
Forest virus, Bebaru virus, Cabassou virus, Chikungunya virus,
Eastern equine encephalitis virus, Everglades virus, Fort Morgan
virus, Getah virus, Highlands J virus, Kyzylagach virus, Mayaro
virus, Me Tri virus, Middelburg virus, Mosso das Pedras virus,
Mucambo virus, Ndumu virus, O'nyong-nyong virus, Pixuna virus, Rio
Negro virus, Ross River virus, Salmon pancreas disease virus,
Semliki Forest virus, Southern elephant seal virus, Tonate virus,
Trocara virus, Una virus, Venezuelan equine encephalitis virus,
Western equine encephalitis virus, and Whataroa virus.
[0018] Also described herein are cells comprising the vectors
described to produce VLPs. These cells may be used to produce the
VLPs described herein by transcribing or expressing the
polynucleotides of the vectors. For instance, a mammalian cell
transfected with a vector having a polynucleotide sequence encoding
an alphavirus RNA construct having a gene or polynucleotide of
interest and a packaging signal, a vector encoding a retroviral gag
protein, and a vector encoding a viral fusion protein could produce
a VLP having the expressed viral fusion protein on its surface with
one or two copies of the encoded alphavirus RNA construct housed
inside the VLP. Furthermore, because none of these vectors encode
alphavirus structural proteins the possibility of creating an
infectious virus is substantially reduced compared to systems that
do include alphavirus structural proteins.
[0019] VLPs produced using the vectors and cells are also described
herein. The VLPs described herein will have four general
characteristics: they will comprise one or two RNA molecules
encoding an alphavirus replicon, and optionally a protein of
interest; they will have a viral core comprising a retroviral gag
protein, or, in some embodiments, a gag fusion protein; they will
have a surface protein to facilitate fusion with a cell, and they
will not contain a polynucleotide that encodes an alphavirus
structural protein.
[0020] The VLPs described herein may be produced in a variety of
ways, as will be apparent to those skilled in the art based on the
provided disclosure. The commonality to these various methods is
the expression of the described vectors in a cell capable of
expressing the necessary proteins (gag and a fusion protein) and
producing the alphavirus-based RNA replicon.
BRIEF DESCRIPTION OF THE DRAWINGS
[0021] FIGS. 1A, 1B and 1C illustrate the elements of the three
vectors exemplified herein. FIG. 1A shows the plasmid pCMV-Sin
Rep-protein of interest-2 (POI-2), which is a Sindbis virus-based
replicon. FIG. 1B shows the plasmid pGAG-protein of interest-1
(POI-1), which encodes a retroviral gag protein. FIG. 1C shows the
plasmid pEnvelope, which encodes the viral fusion protein, such as
VSV-G.
[0022] FIG. 2 schematically shows an example of a vector according
to the description corresponding to the plasmid depicted in FIG.
1A. The DNA sequence of the vector is provided in the Sequence
Listing, appended hereto.
[0023] FIG. 3 schematically represents how the transducing VLPs
described herein are produced.
[0024] FIGS. 4A, 4B and 4C depict the results of three separate VLP
transduction experiments. FIG. 4A shows cells transduced with a
GFP-expressing Sindbis virus replicon packaged into VLPs obtained
from supernatants collected from Baby Hamster Kidney (BHK)-21 cells
transfected with all three plasmids; FIG. 4B shows the absence of
GFP expression in cells incubated with cell supernatants collected
from BHK-21 cells nucleofected with only the pCMV-Sin Rep-POI-2 and
pGAG-POI-1 plasmids in the absence of envelope protein. FIG. 4C
shows transduction of human embryonic kidney (HEK293T) cells to
demonstrate that the constructed VLPs can transduce human
cells.
[0025] FIGS. 5A, 5B, 5C and 5D show that the VLPs described herein
can successfully transduce cells following storage at 4.degree. C.
for 1 hour (FIG. 5A), 2 days (FIG. 5B), 4 days (FIG. 5C), and 8
days (FIG. 5D).
[0026] FIGS. 6A and 6B show the expression levels of Gaussia
luciferase by cells transduced with VLPs having a VEEV replicon
capable of expressing the Gaussia luciferase gene (FIG. 6A,
condition 4). Conditions 1, 2, and 3 of FIG. 6A show expression of
Gaussia luciferase by cells transduced with VEEV replicons having
no exogenous gene (condition 1) or with a gene encoding GFP
(conditions 2 and 3). FIG. 6B provides an illustration of the
expression kinetics of the luciferase protein during the first 4
hours after transduction.
[0027] FIGS. 7A and 7B illustrate the genetic process by the
cre/lox system can be used to alter gene expression in a cell by
delivering cre recombinase to a cell via transduction with a VLP
having a VEEV replicon with the cre recombinase gene (FIG. 7A). The
gene expression profile for a cell line engineered to express GFP
in the absence of cre recombinase and RFP in the presence of cre
recombinase is shown before and after (days 5, 6, and 7)
transduction with a VLP carrying a replicon capable of expressing
cre recombinase. FIG. 7B shows results of delivering functional cre
recombinase (red cells) to cells engineered to express GFP in the
absence of cre recombinase.
[0028] FIG. 8 depicts expression of GFP following transduction of
BHK-21 cells, 293T cells, or NIH3T3 cells with VLPs having either a
Sindbis virus or VEEV-based replicon capable of expressing GFP. 24
and 48-hour time points are shown for all samples.
[0029] FIGS. 9A, 9B, 9C, 9D, 9E, 9F and 9G illustrate functional
packaging of non-coding RNA into VLPs. Cells transduced with VLPs
containing: VEE-rep-GFP (encoding GFP) (FIG. 9A), VEE-Rep miGFP
(encoding microRNA for GFP) (FIG. 9B), VEERep-GFP and VEERep miGFP
(simultaneous transduction) (FIG. 9C), VEERep-GFP and VEERep miGFP
(miRNA transduction occurred 4 hours prior to GFP transduction)
(FIG. 9D), VEE-rep-Cre (used in place of scrambled miRNA to
demonstrate specificity of miRNA) (FIG. 9E), VEE-Rep-GFP and
VEE-Rep-Cre (simultaneous transduction) (FIG. 9F), or VEERep-Cre,
incubation of cells for 4 hr prior to transduction with VLPs
containing VEE-Rep-GFP (FIG. 9G).
[0030] FIGS. 10A and 10B show a schematic representation of an
alphavirus replicon having two different genes (encoding either
HLA-DR1 or CD80) the expression of which can occur in the same cell
(FIG. 10A). Images of cells expressing both proteins following
transduction with a VLP having a replicon shown in FIG. 10A are
provided in FIG. 10B, where HLA-DR1 expression is visualized using
immunospecific labeling with FITC (green) and CD80 is visualized
with immunospecific labeling with phycoerythrin (red); a merged
image is also shown to illustrate coexpression in the same
cells.
[0031] FIG. 11 provides a schematic representation of
pDest472-VEE-MCS.
[0032] FIG. 12 provides a schematic representation of
pDest472-VEE.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0033] Various alphavirus-based expression vectors for transgene
expression in target cells have been described (Xiong C., et al.,
1989, Science 1188-91; and Bredenbeek P. et al., 1993, J. Virol.
6439-46). For safety considerations these expression systems
usually comprise two plasmids. One plasmid contains the coding
sequence of the viral replicon (i.e., non-structural proteins) and
an internal promoter and transgene coding region, while the second
plasmid encodes the viral structural genes. These plasmids are used
to generate mRNA in vitro, which is then electroporated into host
cells to generate one-round infectious virus particles. These viral
particles are then used to infect target cells for transgene
expression. These particles raise safety concerns, however, because
recombination between the sequence elements encoding the
non-structural and the structural viral elements can yield
replication-competent alphavirus particles having the ability to
mediate a significant cytopathic effect in vivo.
[0034] A possible solution to this problem is to use unrelated VLPs
to deliver alphavirus replicons to the cytoplasm of mammalian cells
where they can replicate autonomously and express genes of interest
without any nuclear involvement. These VLPs can be produced using
three vectors. The first vector comprises the coding sequence for
the alphavirus replicon under the control of a mammalian promoter
(e.g., CMV), a retroviral-specific RNA packaging signal, and a gene
or polynucleotide of interest. The gene may express a protein with
therapeutic or research applications, or a shRNA or other
regulatory nucleic acid. The second vector comprises retroviral
Gag. The third vector would provide the suitable envelope
glycoprotein for infection of target cells.
[0035] Upon co-transfection into an appropriate packing cell line,
RNA molecules transcribed from the cellular promoter present in the
first vector will be packaged into VLPs produced from the second
vector. These VLPs can deliver the alphavirus-based replicon to a
target cell based on the envelope glycoprotein present in the VLPs.
Once inside the cell, the host translational machinery will
translate the introduced alphavirus RNA and produce alphavirus
replication proteins, which will in turn amplify the RNA and
express the gene or polynucleotide of interest. Mutant replicons
such as the one described above can greatly prolong the duration of
expression with minimal impact on the host cell. Moreover, DNA
encoding genes for alphavirus structural elements will be absent in
the target cell, so the safety of the proposed system is greatly
enhanced.
[0036] Described herein are compositions relating to VLPs and
methods for making and using the described VLPs. The described
compositions include VLPs, and vectors and cells used to produce
the described VLPs. The related methods described herein relate to
methods of producing the VLPs, methods of transducing cells using
the VLPs, and methods of producing a protein or polynucleotide of
interest in a target cell using the VLPs described herein. Also
described are alphavirus-based replicons that allow for expression
of proteins or polynucleotides of interest in a target cell without
the risk of viral infection.
Definitions
[0037] When the terms "one," "a," or "an" are used in this
disclosure, they mean "at least one" or "one or more," unless
otherwise indicated.
[0038] The term "fusogenic protein" as used herein is meant to
refer to a protein that can induce the fusion of the plasma
membrane derived envelope of the VLP to the membrane of the
recipient cell.
[0039] The terms "express" and "produce" are used synonymously
herein, and refer to the biosynthesis of a gene product. These
terms encompass the transcription of a gene into RNA. These terms
also encompass translation of RNA into one or more polypeptides,
and further encompass all naturally occurring post-transcriptional
and post-translational modifications. The expression or production
of an antibody or antigen-binding fragment thereof may be within
the cytoplasm of the cell, or into the extracellular milieu such as
the growth medium of a cell culture.
[0040] "Polynucleotide," synonymously referred to as "nucleic acid
molecule," "nucleotides" or "nucleic acids," refers to any
polyribonucleotide or polydeoxyribonucleotide, which may be
unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides"
include, without limitation single- and double-stranded DNA, DNA
that is a mixture of single- and double-stranded regions, single-
and double-stranded RNA, and RNA that is mixture of single- and
double-stranded regions, hybrid molecules comprising DNA and RNA
that may be single-stranded or, more typically, double-stranded or
a mixture of single- and double-stranded regions. In addition,
"polynucleotide" refers to triple-stranded regions comprising RNA
or DNA or both RNA and DNA. The term polynucleotide also includes
DNAs or RNAs containing one or more modified bases and DNAs or RNAs
with backbones modified for stability or for other reasons.
"Modified" bases include, for example, tritylated bases and unusual
bases such as inosine. A variety of modifications may be made to
DNA and RNA; thus, "polynucleotide" embraces chemically,
enzymatically or metabolically modified forms of polynucleotides as
typically found in nature, as well as the chemical forms of DNA and
RNA characteristic of viruses and cells. "Polynucleotide" also
embraces relatively short nucleic acid chains, often referred to as
oligonucleotides.
[0041] "Replicon" as used herein refers to a polynucleotide having
the genetic elements necessary to facilitate replication of its
sequence and while also being capable of undergoing
translation.
[0042] "Virus-like particle" (VLP), as used herein, refers to a
structure resembling a virus particle. In preferred embodiments, a
VLP contains at least one fusogenic protein displayed on the
surface of the particle. A virus-like particle in accordance with
the invention lacks all or part of the replicative components of
the viral genome. Typically, a virus-like particle in accordance
with the invention does not carry genetic information encoding for
the proteins of the virus-like particle.
Vectors
[0043] Described herein are vectors for use in producing VLPs
carrying an alphavirus-based replicon that does not encode
alphavirus structural proteins. To produce VLPS of this sort,
several components may be produced by transfecting or nucleofecting
one or more vectors encoding these components into a cell line for
in vitro production. In some embodiments, these components are
encoded by separate vectors to reduce the likelihood that the
resulting VLP will be replication competent. For example, a
multi-plasmid system may be used where one plasmid encodes the
genetic material, such as an RNA polynucleotide encoding Sindbis
virus or VEEV nonstructural proteins, to be packaged by the VLP;
another encodes the structural proteins of the VLP, such as gag;
and another plasmid encodes a fusion protein, such as VSV-G, to
facilitate fusion of the VLP to the membrane of a target cell.
[0044] The vectors encoding the genetic material to be packaged by
a host cell can take a variety of forms, such as selectable or
inducible plasmids, but generally have some common characteristics.
For example, vectors encoding an RNA alphavirus-based replicon
described herein may include a promoter sequence, a retroviral
packaging signal sequence, translation initiation sequences,
nonstructural alphavirus proteins, a cloning site for inserting a
gene or polynucleotide of interest, an inserted gene or
polynucleotide of interest, a 3' untranslated region, and a
poly-adenosine tail segment.
[0045] In some embodiments the described vectors include a promoter
element that allows for segments of the vector to be transcribed by
a host cell. In some embodiments the vector sequence may be
transcribed into RNA to be packaged into a VLP. In most embodiments
of the described vectors, the promoter sequence will be located
upstream of all of the translatable elements included within the
vector (see for example, FIG. 1(a) illustrating the location of the
cytomegalovirus promoter "pCMV"). In some embodiments described
herein the promoter sequence will be derived from a virus, such as
cytomegalovirus (CMV), or simian virus 40 (SV40). Numerous other
promoter sequences are well known to those skilled in the art and
their use with the vectors described herein would be apparent based
on the description provided.
[0046] In some embodiments the described vectors encoding the
genetic material to be packaged by a host cell can include a
polynucleotide sequence that encodes a retroviral packaging signal
sequence (also known as a psi (.psi.) element) to allow one or two
copies of the RNA sequence transcribed from the vector to be
packaged into a VLP particle formed in a host cell. Most, if not
all, retroviruses have a packaging sequence of this nature, thus
these sequences, and their incorporation into the described
vectors, will be readily apparent to those skilled in the art. In
some embodiments the vectors described herein include a
polynucleotide sequence that encodes a retroviral packaging
sequence derived from Rous sarcoma virus, Moloney murine leukemia
virus, simian immunodeficiency virus (SIV), HIV, human
T-lymphotropic virus, and the like. In a particular embodiment, the
retroviral packaging sequence is derived from Rous sarcoma virus.
Alternatively, the retroviral packaging sequence is derived from
murine leukemia virus.
[0047] Another aspect of the vectors encoding the genetic material
to be packaged by a host cell described herein are translation
initiation sequences, which allow the RNA sequence encoded by the
vector to be translated in a host cell. In some embodiments the
described translation initiation sequences may be capable of
allowing for expression of alphavirus-based nonstructural proteins,
which can replicate the RNA sequence carried by the described VLPs
once it is delivered to the host cell. In some embodiments, the
described translation initiation sequences may be capable of
allowing for expression of a gene of interest. In some embodiments
the translation initiation sequence may allow for the gene of
interest to be translated by host cell translation complexes. In
some embodiments the translation initiation sequences described
herein may be derived from an alphavirus, such as Sindbis virus or
VEEV. In other embodiments the translation initiation sequences may
be derived from other genes, such as virus genes known to have
translation initiation sequences capable of initiating translation
of an RNA sequence by mammalian translation complexes.
Alternatively, the translation initiation sequences may be derived
from other genes, such as the native translation initiation
sequence of the gene of interest inserted into the described
alphavirus replicon. In some embodiments the translation initiation
sequences described herein may be located at more than one location
in the packaged RNA molecule, and thus may be encoded one or more
times by the described vectors. For example, it may be desirable to
translate the described Sindbis or VEEV nonstructural proteins
separately from a gene of interest encoded by the package RNA
molecule. In such an instance, both the polynucleotide(s) encoding
the nonstructural proteins and the polynucleotide encoding the
protein of interest will have separate translation initiation
sequences located 5' of their position in the vector and packaged
RNA. Based on this description, those skilled in the art will
understand that a variety of translation initiation sequences
capable of promoting the translation of RNA in a mammalian cell may
be incorporated to the described VLP-packaged RNAs described
herein.
[0048] The vectors encoding genetic material to be packaged by a
host cell may also include polynucleotides that encode
nonstructural alphavirus proteins, such as nonstructural proteins
from Sindbis virus or VEEV. For example, in some embodiments the
described vectors may include polynucleotides that encode one or
more Sindbis virus nonstructural proteins. In some embodiments the
described vectors may include polynucleotides that encode one or
more VEEV nonstructural proteins. In some embodiments described
vectors may include polynucleotides that encode the Sindbis virus
or VEEV nonstructural protein NSP1. In some embodiments described
vectors may include polynucleotides that encode the Sindbis virus
or VEEV nonstructural protein NSP2. In some embodiments described
vectors may include polynucleotides that encode the Sindbis virus
or VEEV nonstructural protein NSP3. In some embodiments described
vectors may include polynucleotides that encode the Sindbis virus
or VEEV nonstructural protein NSP4. In some embodiments described
vectors may include polynucleotides that encode the Sindbis virus
or VEEV nonstructural proteins NSP1, NSP2, NSP3, and NSP4. In some
embodiments the polynucleotide of the described vector that encodes
the alphavirus nonstructural proteins will be derived from the
corresponding genomic sequence of an alphavirus genome, such as
that of Sindbis virus or VEEV. In some embodiments, the
polynucleotides encoding the alphavirus nonstructural proteins are
void of any polynucleotides that encode the alphavirus structural
proteins, regardless of whether the structural proteins are from
the same or a different alphavirus than the nonstructural protein
sequences present.
[0049] The vector described herein for incorporating genetic
material to be packaged by a host cell may also contain a
polynucleotide of interest that may be expressed in a host cell
transduced by a VLP carrying the genetic material encoded by the
vector. In some embodiments the described vectors may encode an RNA
polynucleotide sequence to be packaged into a VLP, which can then
be delivered to a host cell by VLP-mediated transduction of the
cell. Once the RNA polynucleotide sequence has been delivered to
the target cell a polynucleotide of interest encoded by the RNA may
provide for expression of a protein of interest. Accordingly, the
vectors described herein are designed to encode an RNA for
packaging into a VLP that can express a gene of interest once
inside a target cell. Therefore, in some embodiments the described
vectors will include a polynucleotide sequence of interest. In some
embodiments of the described vector, the polynucleotide sequence of
interest may encode a protein of interest. For example, the
polynucleotide sequence of interest may encode GFP in some
embodiments and serve a detectable marker of viral transduction of
a target cell. In another embodiment, the polynucleotide sequence
of interest may encode a functional version of a protein endogenous
to the target cell. In another embodiment, the polynucleotide
sequence of interest may encode a functional version of a protein
endogenous to the target subject. In another embodiment, the
polynucleotide sequence of interest may encode a protein that is
foreign to the target cell. In another embodiment, the
polynucleotide sequence of interest may encode a protein that is
foreign to the target subject. In some embodiments the
polynucleotide sequence of interest may encode a protein capable of
having a therapeutic effect on a target cell. In some embodiments
the polynucleotide sequence of interest may encode a protein
capable of having a therapeutic effect on a target subject. In an
alternative embodiment the polynucleotide sequence of interest may
server as an interfering RNA molecule and function to regulate
endogenous gene expression in a host cell. For example, in some
embodiments the polynucleotide sequence of interest may comprise a
sequence that provides for the formation of an RNA hairpin loop to
initiate RNA interference. In addition, the polynucleotide of
interest could be a positive or negative sense strand of RNA that
can be transcribed by the RNA-dependent RNA polymerase complex
formed by the alphavirus nonstructural proteins encoded by the
packaged RNA molecule. Since this RNA-dependent RNA polymerase can
transcribe RNA in the positive-sense and negative-sense directions,
an interfering RNA sequence, such as a miRNA or shRNA, may be
inserted into the packaged RNA replicon and can be designed to
encode an interfering polynucleotide in either direction. Those of
skill in the art will appreciate the therapeutic characteristic of
this aspect of the described transduction system, as it can allow
for expression of selected proteins in a subject. In accordance
with this aspect of the described vector, a cloning site having one
or more restriction endonuclease sites may also be included in the
vector, to facilitate insertion of a polynucleotide sequence of
interest.
[0050] Another vector useful in the production of the VLPs
described herein is a vector that encodes a virus structural
protein. One such class of proteins is the retroviral
group-specific antigen (gag) protein. The gag protein is the core
structural protein of retroviruses and, in some instances, is
capable of forming enveloped virus cores when expressed in
eukaryotic cells. This property makes gag proteins particularly
useful in the production of VLPs, because they can form the basic
structural aspect of the particle and allow for packaging of RNA
associated with a retroviral packaging signal sequence.
Accordingly, described herein are vectors that include a
polynucleotide that encodes a retroviral gag protein. In some
embodiments, the described vectors include a polynucleotide that
encodes a retroviral gag protein and a promoter polynucleotide
sequence that allows for the gag gene sequence to be transcribed
into mRNA by host cell RNA polymerase. In one embodiment, the
promoter polynucleotide sequence is derived from a virus, such as
SV40 or CMV. In some embodiments, the vector will further include a
polynucleotide that encodes a protein of interest. Those skilled in
the relevant art will understand that a polynucleotide sequence of
a gag protein from any retrovirus may be used to produce the
vectors and VLPs described herein. In some embodiments the
polynucleotide sequence encoding the gag protein may be derived
from Rous sarcoma virus. In some embodiments the polynucleotide
sequence encoding the gag protein may be derived from murine
leukemia virus. In some embodiments the polynucleotide sequence
encoding the gag protein may be derived from SIV. In some
embodiments the polynucleotide sequence encoding the gag protein
may be derived from human T-lymphotropic virus.
[0051] Another vector useful in the production of the VLPs
described herein is a vector that encodes a protein to mediate
fusion between the VLP envelope and a host cell. A class of
proteins suitable for this purpose is viral fusion proteins, which
facilitate virus infection of cells by allowing an enveloped virus
to fuse its membrane with that of a host cell. Many of viral fusion
proteins also have known, or suspected, cellular receptor proteins
that may allow for targeting of selected cell types, or in cases of
more ubiquitous receptors, such as sialic acid for influenza virus,
more generalized targeting may be desired. In some instances, viral
fusion proteins work in conjunction with viral attachment proteins,
ligands for cellular receptor, a receptor for a cell ligand, or
accessory proteins, thus proteins of this sort may also be encoded
by the described vectors, in addition to, or also by, the vector
encoding a viral fusion protein. Alternatively, in some embodiments
a viral fusion protein from one virus may be encoded by the
described vector along with a viral attachment protein of another
virus, a ligand of a cellular receptor, a receptor of a cell
ligand, or an accessory protein to facilitate, or direct, targeting
of a VLP to a desired cell type. In some embodiments the viral
fusion protein, viral attachment protein, ligand of a cellular
receptor, receptor of a cell ligand, or accessory protein will be a
type-I membrane protein, which will allow the extracellular domain
of the protein to be oriented extracellularly when present on the
cell surface. This will also allow the fusion protein to be
correctly oriented following budding of a VLP from a packaging
cell. Expression of such proteins in a cell will typically result
in the cell surface being coated with the proteins, so that budding
of a VLP from any part of the cell membrane will provide the VLP
with some amount of the protein(s) on its surface. In some
embodiments, the described vectors include a polynucleotide that
encodes a viral fusion protein and a promoter polynucleotide
sequence that allows for the fusion protein gene sequence to be
translated into mRNA by host cell RNA polymerase. In one
embodiment, the promoter polynucleotide sequence is derived from a
virus, such as SV40 or CMV. In some embodiments, the described
vectors include a polynucleotide that encodes a viral attachment
protein and a promoter polynucleotide sequence that allows for the
attachment protein gene sequence to be translated into mRNA by host
cell RNA polymerase. In one embodiment, the promoter polynucleotide
sequence is derived from a virus, such as SV40 or CMV. In some
embodiments the vectors described herein include a polynucleotide
that encodes a vesicular stomatitis virus G protein. In some
embodiments the vectors described herein include a polynucleotide
that encodes the influenza hemaglutinin protein. In some
embodiments the vectors described herein include a polynucleotide
that encodes the influenza neuraminidase protein. In some
embodiments the vectors described herein include a polynucleotide
that encodes the respiratory syncytial virus fusion protein. In
some embodiments the vectors described herein include a
polynucleotide that encodes the rotavirus VP7 protein. Other such
fusion proteins will be apparent to those skilled in the art based
on desired tropism or cell target of the associated virus.
Cells Expressing the Described Vectors
[0052] Provided herein are cells comprising the vectors described
to produce VLPs. These cells may be used to produce the VLPs
described herein by transcribing or expressing the polynucleotides
of the vectors. For instance, a mammalian cell transfected with a
vector having a polynucleotide sequence encoding an alphavirus RNA
construct having a gene or polynucleotide of interest and a
packaging signal, a vector encoding a retroviral gag protein, and a
vector encoding a viral fusion protein could produce a VLP having
the expressed viral fusion protein on its surface with one or two
copies of the encoded alphavirus RNA construct housed inside the
VLP. Furthermore, because none of these vectors encode alphavirus
structural proteins the possibility of creating an infectious virus
is substantially reduced compared to systems that do include
alphavirus structural proteins.
[0053] The described cells may be any eukaryotic cell capable of
transcribing, and where necessary (such as in the case of the gag
and fusion proteins), translating the polynucleotides of the
described vectors. The cells will likely be mammalian cells in many
embodiments. For example, rodent cells, such as murine, hamster
(CHO or BHK-21), or rat cells could be used to express the
described vectors; canine cells, such as Madin Darby canine kidney
cells, could be used to express the described vectors; primate
cells, such as vero cells, could be used to express the described
vectors; and human cells, such as HEK293T cells (human kidney),
Hep-2 cells (human airway), Caco-2 (intestine), HeLa (epithelium),
and other such cell lines known in the art, could be used to
express the described vectors. In some embodiments the described
cells can be transfected and selected, using standard transfection
and selection methods known in the art, to stably comprise one or
more of the described vectors.
[0054] In some embodiments the cell lines described herein will
contain a vector comprising a polynucleotide sequence encoding an
alphavirus replicon wherein the alphavirus replicon encodes a
protein of interest, a vector comprising a polynucleotide sequence
encoding a gag protein, and a vector comprising a polynucleotide
sequence encoding a heterologous fusogenic envelope protein,
wherein neither the vectors nor the cell contain a gene encoding an
alphavirus structural protein. In some embodiments the alphavirus
replicon may be derived from Sindbis virus or VEEV. In some
embodiments the alphavirus replicon may have polynucleotide
sequences that encode Sindbis virus or VEEV nonstructural proteins
NSP1, NSP2, NSP3, NSP4, and a retroviral packaging signal. In some
embodiments the retroviral packaging signal may be derived from
either Rous sarcoma virus or murine leukemia virus. In some
embodiments the polynucleotide sequence encoding the gag protein is
derived from Rous sarcoma virus. In some embodiments the
polynucleotide sequence encoding the heterologous fusogenic
envelope protein encodes VSV-G.
Virus-Like Particles
[0055] VLPs produced using the vectors and cells are also described
herein. The VLPs described herein will have four general
characteristics: they will comprise one or two RNA molecules
encoding an alphavirus replicon, and optionally a protein of
interest; they will have a viral core comprising a retroviral gag
protein, or, in some embodiments, a gag fusion protein; they will
have a surface protein to facilitate fusion with a cell, and they
will not contain a polynucleotide that encodes an alphavirus
structural protein.
[0056] The VLPs described herein will be useful in transducing
cells in order to express a protein of interest therein.
Accordingly, the described VLPs may incorporate one or two
alphavirus-based RNA polynucleotides capable of encoding a protein
of interest. To facilitate translation of the RNA sequence some
embodiments of the described packaged RNA may include translation
initiation sequences as described herein. In some embodiments the
RNA sequence incorporated into the VLP will include a retroviral
packaging sequence that will facilitate inclusion of the RNA into a
forming VLP. In some embodiments the retroviral packaging sequence
is derived from Rous sarcoma virus, Moloney murine leukemia virus,
simian immunodeficiency virus (SIV), HIV, human T-lymphotropic
virus, and the like. In a particular embodiment, the retroviral
packaging sequence is derived from Rous sarcoma virus.
Alternatively, the retroviral packaging sequence may be derived
from murine leukemia virus. In addition, the RNA sequences included
in the VLP may be capable of encoding nonstructural alphavirus
proteins. For example, in some embodiments the packaged RNA may
encode one or more Sindbis virus or VEEV nonstructural proteins. In
some embodiments the packaged RNA may encode the Sindbis virus or
VEEV nonstructural protein NSP1. In some embodiments the packaged
RNA may encode the Sindbis virus or VEEV nonstructural protein
NSP2. In some embodiments the packaged RNA may encode the Sindbis
virus or VEEV nonstructural protein NSP3. In some embodiments the
packaged RNA may encode the Sindbis virus or VEEV nonstructural
protein NSP4. In some embodiments the packaged RNA may encode the
Sindbis virus or VEEV nonstructural proteins NSP1, NSP2, NSP3, and
NSP4. The packaged RNA may also include the polynucleotide sequence
of a protein of interest. For example, the polynucleotide sequence
of interest may encode GFP in some embodiments and serve a
detectable marker of viral transduction of a target cell. In
another embodiment, the polynucleotide sequence of interest may
encode a functional version of a protein endogenous to the target
cell. In another embodiment, the polynucleotide sequence of
interest may encode a functional version of a protein endogenous to
the target subject. In another embodiment, the polynucleotide
sequence of interest may encode a protein that is foreign to the
target cell. In another embodiment, the polynucleotide sequence of
interest may encode a protein that is foreign to the target
subject. In some embodiments the polynucleotide sequence of
interest may encode a protein capable of having a therapeutic
effect on a target cell. In some embodiments the polynucleotide
sequence of interest may encode a protein capable of having a
therapeutic effect on a target subject. Those of skill in the art
will appreciate the therapeutic characteristic of this aspect of
the described VLPs, as they can allow for expression of selected
proteins in a cell or subject.
[0057] The described VLPs may also comprise a viral gag protein to
provide a viral core structure to the particle. The gag protein is
the core structural protein of retroviruses and, in some instances,
is capable of forming enveloped virus cores when expressed in
eukaryotic cells. This property makes gag proteins particularly
useful in the production of VLPs, because they can form the basic
structural aspect of the particle and allow for packaging of RNA
associated with a retroviral packaging signal sequence. Those
skilled in the relevant art will understand that a gag protein from
any retrovirus may be used to produce the vectors and VLPs
described herein. In some embodiments the gag protein may be
derived from Rous sarcoma virus. In some embodiments the gag
protein may be derived from murine leukemia virus. In alternative
embodiments the gag protein may be derived from SIV, HIV, human
T-lymphotropic virus, or similar retrovirus.
[0058] Another component of the VLPs described herein is a protein
to mediate fusion between the VLP envelope and a host cell. A class
of proteins suitable for this purpose is viral fusion proteins,
which facilitate virus infection of cells by allowing an enveloped
virus to fuse its membrane with that of a host cell. Many of viral
fusion proteins also have known, or suspected, cellular receptor
proteins that may allow for targeting of selected cell types, or in
cases of more ubiquitous receptors, such as sialic acid for
influenza virus, more generalized targeting may be achieved. In
some instances, viral fusion proteins may work in conjunction with
viral attachment proteins, ligands of cellular receptors, receptors
of cellular ligands, or accessory proteins, thus proteins of this
sort may also be present on the VLP surface in addition to a viral
fusion protein. Alternatively, in some embodiments the described
VLPs may have a viral fusion protein from one virus and a viral
attachment protein of another virus, a ligand of a cellular
receptor, a receptor of a cellular ligand, or an accessory protein
to facilitate, or direct, targeting of a VLP to a desired cell
type. Similarly, the described VLPs may be produced to have more
than one fusion protein in the VLP envelope, as this may facilitate
fusion to a select variety of cell types. In some embodiments the
VLP surface protein(s) will be a type-I membrane protein, which
will allow the extracellular domain of the protein to be oriented
extracellularly when present on the cell surface. This will also
allow the fusion protein to be correctly oriented following budding
of a VLP from a packaging cell. Expression of such proteins in a
cell will typically result in the cell surface being coated with
the proteins, so that budding of a VLP from any part of the cell
membrane will provide the VLP with some amount of the fusion
protein on its surface. In some embodiments the VLPs described
herein include a vesicular stomatitis virus G protein (VSV-G) to
mediate cell fusion. In some embodiments the VLPs described herein
include an influenza hemaglutinin protein to mediate cell fusion.
In some embodiments the VLPs described herein include an influenza
neuraminidase protein to facilitate cell fusion. In some
embodiments the VLPs described herein include respiratory syncytial
virus fusion protein. In some embodiments the VLPs described herein
include the rotavirus VP7 protein. Other such fusion proteins will
be apparent to those skilled in the art based on desired tropism or
cell target of the associated virus.
[0059] The VLPs described herein may comprise an alphavirus
replicon, wherein the alphavirus replicon includes a polynucleotide
of interest or encodes a protein of interest, retroviral gag
protein, and heterologous fusogenic envelope protein; wherein the
VLP does not contain an alphavirus structural protein gene. In some
embodiments the alphavirus replicon of the VLP is derived from
Sindbis virus or VEEV. For example, the VLPs described herein may
have an alphavirus replicon encoding Sindbis virus or VEEV
nonstructural proteins NSP1, NSP2, NSP3, and NSP4. In some
embodiments the retroviral packaging signal associated with the
packaged RNA in the described VLPs is derived from either Rous
sarcoma virus or murine leukemia virus. Based on this description,
those skilled in the art will readily understand that the described
VLPs may be modified to incorporate aspects of viruses that may
facilitate VLP stability, RNA packaging, or cell entry. Such
modifications should be understood to be within the scope of the
disclosures provided herein.
Methods of Producing the Described VLPs
[0060] The VLPs described herein may be produced in a variety of
ways, as will be apparent to those skilled in the art based on the
provided disclosure. The commonality to these various methods is
the expression of the described vectors in a cell capable of
expressing the necessary proteins (gag and a fusion protein) and
producing the alphavirus-based RNA replicon. Accordingly, a method
of producing a VLP described herein may include co-transforming,
transfecting, or nucleofecting a eukaryotic cell with a vector
comprising a polynucleotide sequence encoding an alphavirus
replicon, wherein the alphavirus replicon includes a polynucleotide
of interest or encodes a protein of interest; a vector comprising a
polynucleotide sequence encoding a retroviral gag protein; and a
vector comprising a polynucleotide sequence encoding a heterologous
fusogenic envelope protein; and culturing the co-transformed cell
under conditions suitable to cause each vector to produce its
encoded product, thereby producing a virus-like particle. In some
embodiments the polynucleotide sequence encoding the alphavirus
replicon may be derived from Sindbis virus or VEEV. In some
embodiments the alphavirus replicon may have polynucleotide
sequences that encode Sindbis virus or VEEV nonstructural proteins
NSP1, NSP2, NSP3, NSP4, and a retroviral packaging signal. In some
embodiments the retroviral packaging signal may be derived from
either Rous sarcoma virus or murine leukemia virus. In some
embodiments the polynucleotide sequence encoding the gag protein is
derived from Rous sarcoma virus. In some embodiments the
polynucleotide sequence encoding the heterologous fusogenic
envelope protein encodes VSV-G.
Compositions and Methods of Administration
[0061] Described herein are compositions comprising at least one
described VLP and a pharmaceutically acceptable carrier. Such
compositions are useful, for example, for administration to
subjects in need of expression of an exogenous protein or increased
expression of a protein normally found in those of the same species
as the subject. The compositions may be formulated as any of
various preparations that are known and suitable in the art,
including those described and exemplified herein. In some
embodiments, the compositions are aqueous formulations. Aqueous
solutions may be prepared by admixing the VLPs in water or suitable
physiologic buffer, and optionally adding suitable colorants,
flavors, preservatives, stabilizing and thickening agents and the
like as desired. Aqueous suspensions may also be made by dispersing
the VLPs in water or physiologic buffer with viscous material, such
as natural or synthetic gums, resins, methylcellulose, sodium
carboxymethylcellulose, and other well-known suspending agents.
[0062] The compositions may be formulated for injection into a
subject. For injection, the compositions described may be
formulated in aqueous solutions such as water or in physiologically
compatible buffers such as Hanks's solution, Ringer's solution, or
physiological saline buffer. The solution may contain one or more
formulatory agents such as suspending, stabilizing or dispersing
agents. Injection formulations may also be prepared as solid form
preparations which are intended to be converted, shortly before
use, to liquid form preparations suitable for injection, for
example, by constitution with a suitable vehicle, such as sterile
water, saline solution, or alcohol, before use.
[0063] The compositions may be formulated for aerosolized delivery
to a subject. For aerosol delivery, the compositions described may
be formulated in aqueous solutions such as water or in
physiologically compatible buffers such as Hanks's solution,
Ringer's solution, or physiological saline buffer. The solution may
contain one or more formulatory agents such as suspending,
stabilizing or dispersing agents.
[0064] The compositions may be formulated in sustained release
vehicles or depot preparations. Such long-acting formulations may
be administered by implantation (for example subcutaneously or
intramuscularly) or by intramuscular injection. Thus, for example,
the compositions may be formulated with suitable polymeric or
hydrophobic materials (for example, as an emulsion in an acceptable
oil) or ion exchange resins, or as sparingly soluble derivatives,
for example, as a sparingly soluble salt. Liposomes and emulsions
are well-known examples of delivery vehicles suitable for use as
carriers for hydrophobic drugs.
[0065] The following examples are provided for illustrative
purposes and are meant to enhance, not limit, the preceding
disclosure.
EXAMPLE 1
Production of an Alphavirus-Based Gene Expression System
[0066] An alphavirus gene expression system was designed to allow
for VLP-mediated delivery an exogenous gene of interest (GOI) or
protein of interest (POI) to a target cell with low risk of causing
cytopathic viral infection. The expression system was designed
using three vectors, which can be expressed in a packaging cell
line to produce a transducing VLP. One vector codes for the
alphavirus-based expression construct, another vector codes for a
retroviral gag protein to facilitate VLP formation, and a third
vector codes for a fusion protein to mediate VLP fusion to the host
cell. In addition, the system was constructed to work without the
need for alphavirus structural proteins being present.
[0067] To accomplish this, an alphavirus-based DNA plasmid was
produced having a cytomegalovirus promoter (CMV); followed by a
retroviral packaging signal of respective retroviral packaging
protein GAG; followed by a Sindbis or VEE virus genes encoding
nonstructural proteins NSP1, NSP2, NSP3, and NSP4; and finally, one
or more subgenomic promoter (SGP; a promoter for virus-encoded
RNA-dependent RNA polymerase, resulting in the formation of mRNA)
to drive expression of a of a gene of interest (GOI), consisting of
a recombinant polynucleotide, and inserted into a multiple cloning
site; a 3' untranslated region (URT); and a polyA tail. FIG. 2
shows an example of such an alphavirus-based DNA plasmid. In
another version of this expression vector, the retroviral packaging
signal (GAG) is omitted.
[0068] Another plasmid was constructed to encode a retroviral gag
protein and a second, optional protein of interest (POI). A third
plasmid was constructed to provide expression of a VSV-G viral
fusion protein. A schematic of an embodiment of these plasmids is
provided in FIG. 1A-1C, respectively. FIG. 1A shows pCMV-Sin
Rep-POI-2, FIG. 1B shows pGAG-POI-1, and FIG. 1C shows pEnv for
VSV-G.
[0069] Once constructed the plasmids were tested for the ability to
produce VLPs carrying a Sindbis virus replicon having a gene of
interest. For these experiments, green fluorescent protein (GFP)
was used as the gene of interest in order to facilitate detection
of delivery and intracellular expression of the gene. To produce
VLPs, each of the three plasmids described above were transfected
into baby hamster kidney (BHK-21) cells using a standard
nucleofection procedure with an Amaxa system according to
manufacturer instructions (Lonza) (FIG. 3).
[0070] Briefly, the BHK-21 cells at 3.times.10.sup.6 were
re-suspended in 100 .mu.l nucleofection solution L (Amaxa) and
transferred to tube containing 4.5 .mu.g of plasmid coding for GAG,
3 plasmid coding for VSV-G glycoprotein and 100 nanograms of
plasmid coding for Sindbis alphavirus replicon or 2.5 micrograms
for VEE replicon (in total volume of 10 .mu.l). The mixture of
cells and plasmids was transferred to nucleofection cuvette and
nucleofected using Amaxa nucleofector II apparatus using settings
for BHK-21. The nucleofected cells were resuspended in 500 .mu.l of
completed culture medium and transferred to tissue culture plate
containing culture medium solution and incubated at 37.degree. C.
for period of 72-96 hr or for 72 hr at 32.degree. C. After this
time supernatants consisting of VLPs and encapsidated alphavirus
replicon was clarified by centrifugation at 3000 RPM/10 min at
4.degree. C., filtered by 0.45 um filter and exposed to 10 units of
DNAse I (turbo.TM.-DNAse (Ambion)) for 30 min at RT. Processed VLPs
were stored at 4.degree. C. or frozen on dry ice and transferred to
-80.degree. C. As a negative control (fusion-defective VLPs),
BHK-21 cells were also nucleofected with only the pCMV-Sin
Rep-POI-2 or VEEV-Rep-POI and pGAG-POI-1 plasmids, but not the
pEnvelope plasmid encoding VSV-G. Following transfection, the cells
were incubated for 48-72 hours in tissue culture medium under
normal growth conditions to allow for plasmid-driven production of
VLPs. Once the transfected cells were finished incubating, the
tissue culture supernatant, which should contain any produced VLPs,
was collected. The collected cell supernatants were then added to
cultured BHK-21 cells to determine if the cells could be
successfully transduced with GFP. As shown in FIG. 4, cell
supernatants collected from BHK-21 cells transfected with all three
plasmids resulted in robust GFP expression when exposed to
untransfected BHK-21 cells (FIG. 4A). Conversely, no GFP expression
was observed for untransfected BHK-21 cells incubated with cell
supernatants collected from BHK-21 cells transfected with only the
pCMV-Sin Rep-POI-2 and pGAG-POI-1 plasmids (FIG. 4B). Similar
experiments were also conducted using human embryonic kidney
(HEK293T) cells to demonstrate that the constructed VLPs could
transduce human cells (FIG. 4C). Furthermore, the constructed VLPs
can also be stored at 4.degree. C. for at least 30 days without
losing the ability to transduce cells (FIG. 5A-5D).
[0071] Experiments were also conducted to assess the ability of
VEEV-based alpha virus replicon to express protein in cells. For
these studies BHK-21 cells were transduced with VLPs having a
Gaussia luciferase gene inserted into a VEEV replicon. Following
transduction, cell supernatants monitored for expression of
luciferase protein. As shown in FIG. 6, high amounts of luciferase
were detected in the supernatants of cells transduced with the VEEV
replicon having the Gaussia luciferase gene (FIG. 6A, condition 4),
relative to control VEEV replicons without an exogenous gene
(condition 1), or with a gene encoding GFP (conditions 2 and 3).
Additionally, expression of the luciferase protein increased
rapidly after transduction (FIG. 6B). Similar results were also
observed in the context of delivering functional cre recombinase
(red cells) to cells engineered to express GFP in the absence of
cre recombinase (FIG. 7B).
[0072] Cells were transduced in parallel with either Sindbis-based
VLPs encoding GFP or VEEV-based VLPs encoding GFP. As shown in FIG.
8, both alphavirus-based VLPs caused robust GFP expression, while
the cells transduced with VEEV-based VLPs were observed to have the
higher expression levels (FIG. 8).
EXAMPLE 2
miRNA Expressed by a VEE Alphavirus Replicon Inhibits Protein
Production
[0073] Experiments were conducted to assess whether an alphavirus
replicon encoding an miRNA sequence could inhibit protein
production. To assess this, BHK-21 cells were transduced with a VLP
replicon encoding GFP, miRNA specific for GFP, or cre recombinase
(FIG. 9). (See the vectors shown in FIGS. 11 and 12, and SEQ ID
NO:1 in Table 1, below.) GFP expression was noticeable reduced when
cells were first transduced with a replicon encoding miRNA for GFP
and then subsequently transduced with a replicon encoding GFP (4
hours after the intial transduction), as compared to cells
transduced with only a replicon encoding GFP (compare FIG. 9A with
FIG. 9D). Conversely, when cells were first transduced with a
replicon encoding cre recombinase and then subsequently transduced
with a replicon encoding GFP (4 hours after the initial
transduction), no significant reduction in GFP expression was
apparent (FIG. 9G).
EXAMPLE 3
Expression of Multiple Proteins in Target Cells Transduced with VEE
VLPs
[0074] To assess whether an alphavirus replicon can express two
separate proteins in the same cell, experiments were performed
using a VEE replicon having HLA-DR1 under the control of one
subgenomic promoter and CD80 under a another subgenomic promotor
(FIG. 10A). Following production of VLPs having the described VEE
replicon, cells were transduced and examined for expression of both
proteins. As shown in FIG. 10B, transduced cells were able to
express both proteins (immunolabled HLA-DR1 is shown in green
(FITC) and CD80 shown in red (phycoerythrin).
TABLE-US-00001 TABLE 1 SEQ ID NO: 1 1 gacggatcgg gagatctccc
gatcccctat ggtgcactct cagtacaatc tgctctgatg 61 ccgcatagtt
aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 121
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc
181 ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg
cgttgacatt 241 gattattgac tagttattaa tagtaatcaa ttacggggtc
attagttcat agcccatata 301 tggagttccg cgttacataa cttacggtaa
atggcccgcc tggctgaccg cccaacgacc 361 cccgcccatt gacgtcaata
atgacgtatg ttcccatagt aacgccaata gggactttcc 421 attgacgtca
atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt 481
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt
541 atgcccagta catgacctta tgggactttc ctacttggca gtacatctac
gtattagtca 601 tcgctattac catggtgatg cggttttggc agtacatcaa
tgggcgtgga tagcggtttg 661 actcacgggg atttccaagt ctccacccca
ttgacgtcaa tgggagtttg ttttggcacc 721 aaaatcaacg ggactttcca
aaatgtcgta acaactccgc cccattgacg caaatgggcg 781 gtaggcgtgt
acggtgggag gtctatataa gcagagctcg tatggacata ttgtcgttag 841
aacgcggcta caattaatac ataaccttat gtatcataca catacgattt aggggacact
901 atagattgac ggcgtagtac acactattga atcaaacagc cgaccaattg
cactaccatc 961 acaatggaga agccagtagt aaacgtagac gtagaccccc
agagtccgtt tgtcgtgcaa 1021 ctgcaaaaaa gcttcccgca atttgaggta
gtagcacagc aggtcactcc aaatgaccat 1081 gctaatgcca gagcattttc
gcatctggcc agtaaactaa tcgagctgga ggttcctacc 1141 acagcgacga
tcttggacat aggcagcgca ccggctcgta gaatgttttc cgagcaccag 1201
tatcattgtg tctgccccat gcgtagtcca gaagacccgg accgcatgat gaaatacgcc
1261 agtaaactgg cggaaaaagc gtgcaagatt acaaacaaga acttgcatga
gaagattaag 1321 gatctccgga ccgtacttga tacgccggat gctgaaacac
catcgctctg ctttcacaac 1381 gatgttacct gcaacatgcg tgccgaatat
tccgtcatgc aggacgtgta tatcaacgct 1441 cccggaacta tctatcatca
ggctatgaaa ggcgtgcgga ccctgtactg gattggcttc 1501 gacaccaccc
agttcatgtt ctcggctatg gcaggttcgt accctgcgta caacaccaac 1561
tgggccgacg agaaagtcct tgaagcgcgt aacatcggac tttgcagcac aaagctgagt
1621 gaaggtagga caggaaaatt gtcgataatg aggaagaagg agttgaagcc
cgggtcgcgg 1681 gtttatttct ccgtaggatc gacactttat ccagaacaca
gagccagctt gcagagctgg 1741 catcttccat cggtgttcca cttgaatgga
aagcagtcgt acacttgccg ctgtgataca 1801 gtggtgagtt gcgaaggcta
cgtagtgaag aaaatcacca tcagtcccgg gatcacggga 1861 gaaaccgtgg
gatacgcggt tacacacaat agcgagggct tcttgctatg caaagttact 1921
gacacagtaa aaggagaacg ggtatcgttc cctgtgtgca cgtacatccc ggccaccata
1981 tgcgatcaga tgactggtat aatggccacg gatatatcac ctgacgatgc
acaaaaactt 2041 ctggttgggc tcaaccagcg aattgtcatt aacggtagga
ctaacaggaa caccaacacc 2101 atgcaaaatt accttctgcc gatcatagca
caagggttca gcaaatgggc taaggagcgc 2161 aaggatgatc ttgataacga
gaaaatgctg ggtactagag aacgcaagct tacgtatggc 2221 tgcttgtggg
cgtttcgcac taagaaagta cattcgtttt atcgcccacc tggaacgcag 2281
acctgcgtaa aagtcccagc ctcttttagc gcttttccca tgtcgtccgt atggacgacc
2341 tctttgccca tgtcgctgag gcagaaattg aaactggcat tgcaaccaaa
gaaggaggaa 2401 aaactgctgc aggtctcgga ggaattagtc atggaggcca
aggctgcttt tgaggatgct 2461 caggaggaag ccagagcgga gaagctccga
gaagcacttc caccattagt ggcagacaaa 2521 ggcatcgagg cagccgcaga
agttgtctgc gaagtggagg ggctccaggc ggacatcgga 2581 gcagcattag
ttgaaacccc gcgcggtcac gtaaggataa tacctcaagc aaatgaccgt 2641
atgatcggac agtatatcgt tgtctcgcca aactctgtgc tgaagaatgc caaactcgca
2701 ccagcgcacc cgctagcaga tcaggttaag atcataacac actccggaag
atcaggaagg 2761 tacgcggtcg aaccatacga cgctaaagta ctgatgccag
caggaggtgc cgtaccatgg 2821 ccagaattcc tagcactgag tgagagcgcc
acgttagtgt acaacgaaag agagtttgtg 2881 aaccgcaaac tataccacat
tgccatgcat ggccccgcca agaatacaga agaggagcag 2941 tacaaggtta
caaaggcaga gcttgcagaa acagagtacg tgtttgacgt ggacaagaag 3001
cgttgcgtta agaaggaaga agcctcaggt ctggtcctct cgggagaact gaccaaccct
3061 ccctatcatg agctagctct ggagggactg aagacccgac ctgcggtccc
gtacaaggtc 3121 gaaacaatag gagtgatagg cacaccgggg tcgggcaagt
cagctattat caagtcaact 3181 gtcacggcac gagatcttgt taccagcgga
aagaaagaaa attgtcgcga aattgaggcc 3241 gacgtgctaa gactgagggg
tatgcagatt acgtcgaaga cagtagattc ggttatgctc 3301 aacggatgcc
acaaagccgt agaagtgctg tacgttgacg aagcgttcgc gtgccacgca 3361
ggagcactac ttgccttgat tgctatcgtc aggccccgca agaaggtagt actatgcgga
3421 gaccccatgc aatgcggatt cttcaacatg atgcaactaa aggtacattt
caatcaccct 3481 gaaaaagaca tatgcaccaa gacattctac aagtatatct
cccggcgttg cacacagcca 3541 gttacagcta ttgtatcgac actgcattac
gatggaaaga tgaaaaccac gaacccgtgc 3601 aagaagaaca ttgaaatcga
tattacaggg gccacaaagc cgaagccagg ggatatcatc 3661 ctgacatgtt
tccgcgggtg ggttaagcaa ttgcaaatcg actatcccgg acatgaagta 3721
atgacagccg cggcctcaca agggctaacc agaaaaggag tgtatgccgt ccggcaaaaa
3781 gtcaatgaaa acccactgta cgcgatcaca tcagagcatg tgaacgtgtt
gctcacccgc 3841 actgaggaca ggctagtgtg gaaaaccttg cagggcgacc
catggattaa gcagcccact 3901 aacataccta aaggaaactt tcaggctact
atagaggact gggaagctga acacaaggga 3961 ataattgctg caataaacag
ccccactccc cgtgccaatc cgttcagctg caagaccaac 4021 gtttgctggg
cgaaagcatt ggaaccgata ctagccacgg ccggtatcgt acttaccggt 4081
tgccagtgga gcgaactgtt cccacagttt gcggatgaca aaccacattc ggccatttac
4141 gccttagacg taatttgcat taagtttttc ggcatggact tgacaagcgg
actgttttct 4201 aaacagagca tcccactaac gtaccatccc gccgattcag
cgaggccggt agctcattgg 4261 gacaacagcc caggaacccg caagtatggg
tacgatcacg ccattgccgc cgaactctcc 4321 cgtagatttc cggtgttcca
gctagctggg aagggcacac aacttgattt gcagacgggg 4381 agaaccagag
ttatctctgc acagcataac ctggtcccgg tgaaccgcaa tcttcctcac 4441
gccttagtcc ccgagtacaa ggagaagcaa cccggcccgg tcaaaaaatt cttgaaccag
4501 ttcaaacacc actcagtact tgtggtatca gaggaaaaaa ttgaagctcc
ccgtaagaga 4561 atcgaatgga tcgccccgat tggcatagcc ggtgcagata
agaactacaa cctggctttc 4621 gggtttccgc cgcaggcacg gtacgacctg
gtgttcatca acattggaac taaatacaga 4681 aaccaccact ttcagcagtg
cgaagaccat gcggcgacct taaaaaccct ttcgcgttcg 4741 gccctgaatt
gccttaaccc aggaggcacc ctcgtggtga agtcctatgg ctacgccgac 4801
cgcaacagtg aggacgtagt caccgctctt gccagaaagt ttgtcagggt gtctgcagcg
4861 agaccagatt gtgtctcaag caatacagaa atgtacctga ttttccgaca
actagacaac 4921 agccgtacac ggcaattcac cccgcaccat ctgaattgcg
tgatttcgtc cgtgtatgag 4981 ggtacaagag atggagttgg agccgcgccg
tcataccgca ccaaaaggga gaatattgct 5041 gactgtcaag aggaagcagt
tgtcaacgca gccaatccgc tgggtagacc aggcgaagga 5101 gtctgccgtg
ccatctataa acgttggccg accagtttta ccgattcagc cacggagaca 5161
ggcaccgcaa gaatgactgt gtgcctagga aagaaagtga tccacgcggt cggccctgat
5221 ttccggaagc acccagaagc agaagccttg aaattgctac aaaacgccta
ccatgcagtg 5281 gcagacttag taaatgaaca taacatcaag tctgtcgcca
ttccactgct atctacaggc 5341 atttacgcag ccggaaaaga ccgccttgaa
gtatcactta actgcttgac aaccgcgcta 5401 gacagaactg acgcggacgt
aaccatctat tgcctggata agaagtggaa ggaaagaatc 5461 gacgcggcac
tccaacttaa ggagtctgta acagagctga aggatgaaga tatggagatc 5521
gacgatgagt tagtatggat tcatccagac agttgcttga agggaagaaa gggattcagt
5581 actacaaaag gaaaattgta ttcgtacttc gaaggcacca aattccatca
agcagcaaaa 5641 gacatggcgg agataaaggt cctgttccct aatgaccagg
aaagtaatga acaactgtgt 5701 gcctacatat tgggtgagac catggaagca
atccgcgaaa agtgcccggt cgaccataac 5761 ccgtcgtcta gcccgcccaa
aacgttgccg tgcctttgca tgtatgccat gacgccagaa 5821 agggtccaca
gacttagaag caataacgtc aaagaagtta cagtatgctc ctccaccccc 5881
cttcctaagc acaaaattaa gaatgttcag aaggttcagt gcacgaaagt agtcctgttt
5941 aatccgcaca ctcccgcatt cgttcccgcc cgtaagtaca tagaagtgcc
agaacagcct 6001 accgctcctc ctgcacaggc cgaggaggcc cccgaagttg
tagcgacacc gtcaccatct 6061 acagctgata acacctcgct tgatgtcaca
gacatctcac tggatatgga tgacagtagc 6121 gaaggctcac ttttttcgag
ctttagcgga tcggacaact ctattactag tatggacagt 6181 tggtcgtcag
gacctagttc actagagata gtagaccgaa ggcaggtggt ggtggctgac 6241
gttcatgccg tccaagagcc tgcccctatt ccaccgccaa ggctaaagaa gatggcccgc
6301 ctggcagcgg caagaaaaga gcccactcca ccggcaagca atagctctga
gtccctccac 6361 ctctcttttg gtggggtatc catgtccctc ggatcaattt
tcgacggaga gacggcccgc 6421 caggcagcgg tacaacccct ggcaacaggc
cccacggatg tgcctatgtc tttcggatcg 6481 ttttccgacg gagagattga
tgagctgagc cgcagagtaa ctgagtccga acccgtcctg 6541 tttggatcat
ttgaaccggg cgaagtgaac tcaattatat cgtcccgatc agccgtatct 6601
tttccactac gcaagcagag acgtagacgc aggagcagga ggactgaata ctgactaacc
6661 ggggtaggtg ggtacatatt ttcgacggac acaggccctg ggcacttgca
aaagaagtcc 6721 gttctgcaga accagcttac agaaccgacc ttggagcgca
atgtcctgga aagaattcat 6781 gccccggtgc tcgacacgtc gaaagaggaa
caactcaaac tcaggtacca gatgatgccc 6841 accgaagcca acaaaagtag
gtaccagtct cgtaaagtag aaaatcagaa agccataacc 6901 actgagcgac
tactgtcagg actacgactg tataactctg ccacagatca gccagaatgc 6961
tataagatca cctatccgaa accattgtac tccagtagcg taccggcgaa ctactccgat
7021 ccacagttcg ctgtagctgt ctgtaacaac tatctgcatg agaactatcc
gacagtagca 7081 tcttatcaga ttactgacga gtacgatgct tacttggata
tggtagacgg gacagtcgcc 7141 tgcctggata ctgcaacctt ctgccccgct
aagcttagaa gttacccgaa aaaacatgag 7201 tatagagccc cgaatatccg
cagtgcggtt ccatcagcga tgcagaacac gctacaaaat 7261 gtgctcattg
ccgcaactaa aagaaattgc aacgtcacgc agatgcgtga actgccaaca 7321
ctggactcag cgacattcaa tgtcgaatgc tttcgaaaat atgcatgtaa tgacgagtat
7381 tgggaggagt tcgctcggaa gccaattagg attaccactg agtttgtcac
cgcatatgta
7441 gctagactga aaggccctaa ggccgccgca ctatttgcaa agacgtataa
tttggtccca 7501 ttgcaagaag tgcctatgga tagattcgtc atggacatga
aaagagacgt gaaagttaca 7561 ccaggcacga aacacacaga agaaagaccg
aaagtacaag tgatacaagc cgcagaaccc 7621 ctggcgactg cttacttatg
cgggattcac cgggaattag tgcgtaggct tacggccgtc 7681 ttgcttccaa
acattcacac gctttttgac atgtcggcgg aggattttga tgcaatcata 7741
gcagaacact tcaagcaagg cgacccggta ctggagacgg atatcgcatc attcgacaaa
7801 agccaagacg acgctatggc gttaaccggt ctgatgatct tggaggacct
gggtgtggat 7861 caaccactac tcgacttgat cgagtgcgcc tttggagaaa
tatcatccac ccatctacct 7921 acgggtactc gttttaaatt cggggcgatg
atgaaatccg gaatgttcct cacacttttt 7981 gtcaacacag ttttgaatgt
cgttatcgcc agcagagtac tagaagagcg gcttaaaacg 8041 tccagatgtg
cagcgttcat tggcgacgac aacatcatac atggagtagt atctgacaaa 8101
gaaatggctg agaggtgcgc cacctggctc aacatggagg ttaagatcat cgacgcagtc
8161 atcggtgaga gaccacctta cttctgcggc ggatttatct tgcaagattc
ggttacttcc 8221 acagcgtgcc gcgtggcgga tcccctgaaa aggctgttta
agttgggtaa accgctccca 8281 gccgacgacg agcaagacga agacagaaga
cgcgctctgc tagatgaaac aaaggcgtgg 8341 tttagagtag gtataacagg
cactttagca gtggccgtga cgacccggta tgaggtagac 8401 aatattacac
ctgtcctact ggcattgaga acttttgccc agagcaaaag agcattccaa 8461
gccatcagag gggaaataaa gcatctctac ggtggtccta aatagtcagc atagtacatt
8521 tcatctgact aatactacaa caccaccacc tctagagctt gccgccacca
tggtgagcaa 8581 gggcgaggag ctgttcaccg gggtggtgcc catcctggtc
gagctggacg gcgacgtgaa 8641 cggccacaag ttcagcgtgt ccggcgaggg
cgagggcgat gccacctacg gcaagctgac 8701 cctgaagttc atctgcacca
ccggcaagct gcccgtgccc tggcccaccc tcgtgaccac 8761 cctgacctac
ggcgtgcagt gcttcagccg ctaccccgac cacatgaagc agcacgactt 8821
cttcaagtcc gccatgcccg aaggctacgt ccaggagcgc accatcttct tcaaggacga
8881 cggcaactac aagacccgcg ccgaggtgaa gttcgagggc gacaccctgg
tgaaccgcat 8941 cgagctgaag ggcatcgact tcaaggagga cggcaacatc
ctggggcaca agctggagta 9001 caactacaac agccacaacg tctatatcat
ggccgacaag cagaagaacg gcatcaaggt 9061 gaacttcaag atccgccaca
acatcgagga cggcagcgtg cagctcgccg accactacca 9121 gcagaacacc
cccatcggcg acggccccgt gctgctgccc gacaaccact acctgagcac 9181
ccagtccgcc ctgagcaaag accccaacga gaagcgcgat cacatggtcc tgctggagtt
9241 cgtgaccgcc gccgggatca ctcacggcat ggacgagctg tacaagtaaa
gcggccgtga 9301 gcatgcaggc cttgggccca atgatccgac cagcaaaact
cgatgtactt ccgaggaact 9361 gatgtgcata atgcatcagg ctggtacatt
agatccccgc ttaccgcggg caatatagca 9421 acactaaaaa ctcgatgtac
ttccgaggaa gcgcagtgca taatgctgcg cagtgttgcc 9481 acataaccac
tatattaacc atttatctag cggacgccaa aaactcaatg tatttctgag 9541
gaagcgtggt gcataatgcc acgcagcgtc tgcataactt ttattatttc ttttattaat
9601 caacaaaatt ttgtttttaa catttcaaaa aaaaaaaaaa aaaaaaaaaa
aaaaaaaaaa 9661 aaagggaatt cctcgattaa ttaagcggcc gctcgagatg
gcacacgtgt tacggtttta 9721 ccgtcgacct ctagctagag cttggcgtaa
tcatggtcat agctgtttcc tgtgtgaaat 9781 tgttatccgc tcacaattcc
acacaacata cgagccggaa gcataaagtg taaagcctgg 9841 ggtgcctaat
gagtgagcta actcacatta attgcgttgc gctcactgcc cgctttccag 9901
tcgggaaacc tgtcgtgcca gctgcattaa tgaatcggcc aacgcgcggg gagaggcggt
9961 ttgcgtattg ggcgctcttc cgcttcctcg ctcactgact cgctgcgctc
ggtcgttcgg 10021 ctgcggcgag cggtatcagc tcactcaaag gcggtaatac
ggttatccac agaatcaggg 10081 gataacgcag gaaagaacat gtgagcaaaa
ggccagcaaa aggccaggaa ccgtaaaaag 10141 gccgcgttgc tggcgttttt
ccataggctc cgcccccctg acgagcatca caaaaatcga 10201 cgctcaagtc
agaggtggcg aaacccgaca ggactataaa gataccaggc gtttccccct 10261
ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata cctgtccgcc
10321 tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta
tctcagttcg 10381 gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac
cccccgttca gcccgaccgc 10441 tgcgccttat ccggtaacta tcgtcttgag
tccaacccgg taagacacga cttatcgcca 10501 ctggcagcag ccactggtaa
caggattagc agagcgaggt atgtaggcgg tgctacagag 10561 ttcttgaagt
ggtggcctaa ctacggctac actagaagaa cagtatttgg tatctgcgct 10621
ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg caaacaaacc
10681 accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag
aaaaaaagga 10741 tctcaagaag atcctttgat cttttctacg gggtctgacg
ctcagtggaa cgaaaactca 10801 cgttaaggga ttttggtcat gagattatca
aaaaggatct tcacctagat ccttttaaat 10861 taaaaatgaa gttttaaatc
aatctaaagt atatatgagt aaacttggtc tgacagttac 10921 caatgcttaa
tcagtgaggc acctatctca gcgatctgtc tatttcgttc atccatagtt 10981
gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc tggccccagt
11041 gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc
aataaaccag 11101 ccagccggaa gggccgagcg cagaagtggt cctgcaactt
tatccgcctc catccagtct 11161 attaattgtt gccgggaagc tagagtaagt
agttcgccag ttaatagttt gcgcaacgtt 11221 gttgccattg ctacaggcat
cgtggtgtca cgctcgtcgt ttggtatggc ttcattcagc 11281 tccggttccc
aacgatcaag gcgagttaca tgatccccca tgttgtgcaa aaaagcggtt 11341
agctccttcg gtcctccgat cgttgtcaga agtaagttgg ccgcagtgtt atcactcatg
11401 gttatggcag cactgcataa ttctcttact gtcatgccat ccgtaagatg
cttttctgtg 11461 actggtgagt actcaaccaa gtcattctga gaatagtgta
tgcggcgacc gagttgctct 11521 tgcccggcgt caatacggga taataccgcg
ccacatagca gaactttaaa agtgctcatc 11581 attggaaaac gttcttcggg
gcgaaaactc tcaaggatct taccgctgtt gagatccagt 11641 tcgatgtaac
ccactcgtgc acccaactga tcttcagcat cttttacttt caccagcgtt 11701
tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa agggaataag ggcgacacgg
11761 aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta
tcagggttat 11821 tgtctcatga gcggatacat atttgaatgt atttagaaaa
ataaacaaat aggggttccg 11881 cgcacatttc cccgaaaagt gccacctgac gtc //
Sequence CWU 1
1
1111913DNAArtificial Sequencesource/note="Description of Artificial
Sequence Synthetic polynucleotide" 1gacggatcgg gagatctccc
gatcccctat ggtgcactct cagtacaatc tgctctgatg 60ccgcatagtt aagccagtat
ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120cgagcaaaat
ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc
180ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg
cgttgacatt 240gattattgac tagttattaa tagtaatcaa ttacggggtc
attagttcat agcccatata 300tggagttccg cgttacataa cttacggtaa
atggcccgcc tggctgaccg cccaacgacc 360cccgcccatt gacgtcaata
atgacgtatg ttcccatagt aacgccaata gggactttcc 420attgacgtca
atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt
480atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc
gcctggcatt 540atgcccagta catgacctta tgggactttc ctacttggca
gtacatctac gtattagtca 600tcgctattac catggtgatg cggttttggc
agtacatcaa tgggcgtgga tagcggtttg 660actcacgggg atttccaagt
ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720aaaatcaacg
ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg
780gtaggcgtgt acggtgggag gtctatataa gcagagctcg tatggacata
ttgtcgttag 840aacgcggcta caattaatac ataaccttat gtatcataca
catacgattt aggggacact 900atagattgac ggcgtagtac acactattga
atcaaacagc cgaccaattg cactaccatc 960acaatggaga agccagtagt
aaacgtagac gtagaccccc agagtccgtt tgtcgtgcaa 1020ctgcaaaaaa
gcttcccgca atttgaggta gtagcacagc aggtcactcc aaatgaccat
1080gctaatgcca gagcattttc gcatctggcc agtaaactaa tcgagctgga
ggttcctacc 1140acagcgacga tcttggacat aggcagcgca ccggctcgta
gaatgttttc cgagcaccag 1200tatcattgtg tctgccccat gcgtagtcca
gaagacccgg accgcatgat gaaatacgcc 1260agtaaactgg cggaaaaagc
gtgcaagatt acaaacaaga acttgcatga gaagattaag 1320gatctccgga
ccgtacttga tacgccggat gctgaaacac catcgctctg ctttcacaac
1380gatgttacct gcaacatgcg tgccgaatat tccgtcatgc aggacgtgta
tatcaacgct 1440cccggaacta tctatcatca ggctatgaaa ggcgtgcgga
ccctgtactg gattggcttc 1500gacaccaccc agttcatgtt ctcggctatg
gcaggttcgt accctgcgta caacaccaac 1560tgggccgacg agaaagtcct
tgaagcgcgt aacatcggac tttgcagcac aaagctgagt 1620gaaggtagga
caggaaaatt gtcgataatg aggaagaagg agttgaagcc cgggtcgcgg
1680gtttatttct ccgtaggatc gacactttat ccagaacaca gagccagctt
gcagagctgg 1740catcttccat cggtgttcca cttgaatgga aagcagtcgt
acacttgccg ctgtgataca 1800gtggtgagtt gcgaaggcta cgtagtgaag
aaaatcacca tcagtcccgg gatcacggga 1860gaaaccgtgg gatacgcggt
tacacacaat agcgagggct tcttgctatg caaagttact 1920gacacagtaa
aaggagaacg ggtatcgttc cctgtgtgca cgtacatccc ggccaccata
1980tgcgatcaga tgactggtat aatggccacg gatatatcac ctgacgatgc
acaaaaactt 2040ctggttgggc tcaaccagcg aattgtcatt aacggtagga
ctaacaggaa caccaacacc 2100atgcaaaatt accttctgcc gatcatagca
caagggttca gcaaatgggc taaggagcgc 2160aaggatgatc ttgataacga
gaaaatgctg ggtactagag aacgcaagct tacgtatggc 2220tgcttgtggg
cgtttcgcac taagaaagta cattcgtttt atcgcccacc tggaacgcag
2280acctgcgtaa aagtcccagc ctcttttagc gcttttccca tgtcgtccgt
atggacgacc 2340tctttgccca tgtcgctgag gcagaaattg aaactggcat
tgcaaccaaa gaaggaggaa 2400aaactgctgc aggtctcgga ggaattagtc
atggaggcca aggctgcttt tgaggatgct 2460caggaggaag ccagagcgga
gaagctccga gaagcacttc caccattagt ggcagacaaa 2520ggcatcgagg
cagccgcaga agttgtctgc gaagtggagg ggctccaggc ggacatcgga
2580gcagcattag ttgaaacccc gcgcggtcac gtaaggataa tacctcaagc
aaatgaccgt 2640atgatcggac agtatatcgt tgtctcgcca aactctgtgc
tgaagaatgc caaactcgca 2700ccagcgcacc cgctagcaga tcaggttaag
atcataacac actccggaag atcaggaagg 2760tacgcggtcg aaccatacga
cgctaaagta ctgatgccag caggaggtgc cgtaccatgg 2820ccagaattcc
tagcactgag tgagagcgcc acgttagtgt acaacgaaag agagtttgtg
2880aaccgcaaac tataccacat tgccatgcat ggccccgcca agaatacaga
agaggagcag 2940tacaaggtta caaaggcaga gcttgcagaa acagagtacg
tgtttgacgt ggacaagaag 3000cgttgcgtta agaaggaaga agcctcaggt
ctggtcctct cgggagaact gaccaaccct 3060ccctatcatg agctagctct
ggagggactg aagacccgac ctgcggtccc gtacaaggtc 3120gaaacaatag
gagtgatagg cacaccgggg tcgggcaagt cagctattat caagtcaact
3180gtcacggcac gagatcttgt taccagcgga aagaaagaaa attgtcgcga
aattgaggcc 3240gacgtgctaa gactgagggg tatgcagatt acgtcgaaga
cagtagattc ggttatgctc 3300aacggatgcc acaaagccgt agaagtgctg
tacgttgacg aagcgttcgc gtgccacgca 3360ggagcactac ttgccttgat
tgctatcgtc aggccccgca agaaggtagt actatgcgga 3420gaccccatgc
aatgcggatt cttcaacatg atgcaactaa aggtacattt caatcaccct
3480gaaaaagaca tatgcaccaa gacattctac aagtatatct cccggcgttg
cacacagcca 3540gttacagcta ttgtatcgac actgcattac gatggaaaga
tgaaaaccac gaacccgtgc 3600aagaagaaca ttgaaatcga tattacaggg
gccacaaagc cgaagccagg ggatatcatc 3660ctgacatgtt tccgcgggtg
ggttaagcaa ttgcaaatcg actatcccgg acatgaagta 3720atgacagccg
cggcctcaca agggctaacc agaaaaggag tgtatgccgt ccggcaaaaa
3780gtcaatgaaa acccactgta cgcgatcaca tcagagcatg tgaacgtgtt
gctcacccgc 3840actgaggaca ggctagtgtg gaaaaccttg cagggcgacc
catggattaa gcagcccact 3900aacataccta aaggaaactt tcaggctact
atagaggact gggaagctga acacaaggga 3960ataattgctg caataaacag
ccccactccc cgtgccaatc cgttcagctg caagaccaac 4020gtttgctggg
cgaaagcatt ggaaccgata ctagccacgg ccggtatcgt acttaccggt
4080tgccagtgga gcgaactgtt cccacagttt gcggatgaca aaccacattc
ggccatttac 4140gccttagacg taatttgcat taagtttttc ggcatggact
tgacaagcgg actgttttct 4200aaacagagca tcccactaac gtaccatccc
gccgattcag cgaggccggt agctcattgg 4260gacaacagcc caggaacccg
caagtatggg tacgatcacg ccattgccgc cgaactctcc 4320cgtagatttc
cggtgttcca gctagctggg aagggcacac aacttgattt gcagacgggg
4380agaaccagag ttatctctgc acagcataac ctggtcccgg tgaaccgcaa
tcttcctcac 4440gccttagtcc ccgagtacaa ggagaagcaa cccggcccgg
tcaaaaaatt cttgaaccag 4500ttcaaacacc actcagtact tgtggtatca
gaggaaaaaa ttgaagctcc ccgtaagaga 4560atcgaatgga tcgccccgat
tggcatagcc ggtgcagata agaactacaa cctggctttc 4620gggtttccgc
cgcaggcacg gtacgacctg gtgttcatca acattggaac taaatacaga
4680aaccaccact ttcagcagtg cgaagaccat gcggcgacct taaaaaccct
ttcgcgttcg 4740gccctgaatt gccttaaccc aggaggcacc ctcgtggtga
agtcctatgg ctacgccgac 4800cgcaacagtg aggacgtagt caccgctctt
gccagaaagt ttgtcagggt gtctgcagcg 4860agaccagatt gtgtctcaag
caatacagaa atgtacctga ttttccgaca actagacaac 4920agccgtacac
ggcaattcac cccgcaccat ctgaattgcg tgatttcgtc cgtgtatgag
4980ggtacaagag atggagttgg agccgcgccg tcataccgca ccaaaaggga
gaatattgct 5040gactgtcaag aggaagcagt tgtcaacgca gccaatccgc
tgggtagacc aggcgaagga 5100gtctgccgtg ccatctataa acgttggccg
accagtttta ccgattcagc cacggagaca 5160ggcaccgcaa gaatgactgt
gtgcctagga aagaaagtga tccacgcggt cggccctgat 5220ttccggaagc
acccagaagc agaagccttg aaattgctac aaaacgccta ccatgcagtg
5280gcagacttag taaatgaaca taacatcaag tctgtcgcca ttccactgct
atctacaggc 5340atttacgcag ccggaaaaga ccgccttgaa gtatcactta
actgcttgac aaccgcgcta 5400gacagaactg acgcggacgt aaccatctat
tgcctggata agaagtggaa ggaaagaatc 5460gacgcggcac tccaacttaa
ggagtctgta acagagctga aggatgaaga tatggagatc 5520gacgatgagt
tagtatggat tcatccagac agttgcttga agggaagaaa gggattcagt
5580actacaaaag gaaaattgta ttcgtacttc gaaggcacca aattccatca
agcagcaaaa 5640gacatggcgg agataaaggt cctgttccct aatgaccagg
aaagtaatga acaactgtgt 5700gcctacatat tgggtgagac catggaagca
atccgcgaaa agtgcccggt cgaccataac 5760ccgtcgtcta gcccgcccaa
aacgttgccg tgcctttgca tgtatgccat gacgccagaa 5820agggtccaca
gacttagaag caataacgtc aaagaagtta cagtatgctc ctccaccccc
5880cttcctaagc acaaaattaa gaatgttcag aaggttcagt gcacgaaagt
agtcctgttt 5940aatccgcaca ctcccgcatt cgttcccgcc cgtaagtaca
tagaagtgcc agaacagcct 6000accgctcctc ctgcacaggc cgaggaggcc
cccgaagttg tagcgacacc gtcaccatct 6060acagctgata acacctcgct
tgatgtcaca gacatctcac tggatatgga tgacagtagc 6120gaaggctcac
ttttttcgag ctttagcgga tcggacaact ctattactag tatggacagt
6180tggtcgtcag gacctagttc actagagata gtagaccgaa ggcaggtggt
ggtggctgac 6240gttcatgccg tccaagagcc tgcccctatt ccaccgccaa
ggctaaagaa gatggcccgc 6300ctggcagcgg caagaaaaga gcccactcca
ccggcaagca atagctctga gtccctccac 6360ctctcttttg gtggggtatc
catgtccctc ggatcaattt tcgacggaga gacggcccgc 6420caggcagcgg
tacaacccct ggcaacaggc cccacggatg tgcctatgtc tttcggatcg
6480ttttccgacg gagagattga tgagctgagc cgcagagtaa ctgagtccga
acccgtcctg 6540tttggatcat ttgaaccggg cgaagtgaac tcaattatat
cgtcccgatc agccgtatct 6600tttccactac gcaagcagag acgtagacgc
aggagcagga ggactgaata ctgactaacc 6660ggggtaggtg ggtacatatt
ttcgacggac acaggccctg ggcacttgca aaagaagtcc 6720gttctgcaga
accagcttac agaaccgacc ttggagcgca atgtcctgga aagaattcat
6780gccccggtgc tcgacacgtc gaaagaggaa caactcaaac tcaggtacca
gatgatgccc 6840accgaagcca acaaaagtag gtaccagtct cgtaaagtag
aaaatcagaa agccataacc 6900actgagcgac tactgtcagg actacgactg
tataactctg ccacagatca gccagaatgc 6960tataagatca cctatccgaa
accattgtac tccagtagcg taccggcgaa ctactccgat 7020ccacagttcg
ctgtagctgt ctgtaacaac tatctgcatg agaactatcc gacagtagca
7080tcttatcaga ttactgacga gtacgatgct tacttggata tggtagacgg
gacagtcgcc 7140tgcctggata ctgcaacctt ctgccccgct aagcttagaa
gttacccgaa aaaacatgag 7200tatagagccc cgaatatccg cagtgcggtt
ccatcagcga tgcagaacac gctacaaaat 7260gtgctcattg ccgcaactaa
aagaaattgc aacgtcacgc agatgcgtga actgccaaca 7320ctggactcag
cgacattcaa tgtcgaatgc tttcgaaaat atgcatgtaa tgacgagtat
7380tgggaggagt tcgctcggaa gccaattagg attaccactg agtttgtcac
cgcatatgta 7440gctagactga aaggccctaa ggccgccgca ctatttgcaa
agacgtataa tttggtccca 7500ttgcaagaag tgcctatgga tagattcgtc
atggacatga aaagagacgt gaaagttaca 7560ccaggcacga aacacacaga
agaaagaccg aaagtacaag tgatacaagc cgcagaaccc 7620ctggcgactg
cttacttatg cgggattcac cgggaattag tgcgtaggct tacggccgtc
7680ttgcttccaa acattcacac gctttttgac atgtcggcgg aggattttga
tgcaatcata 7740gcagaacact tcaagcaagg cgacccggta ctggagacgg
atatcgcatc attcgacaaa 7800agccaagacg acgctatggc gttaaccggt
ctgatgatct tggaggacct gggtgtggat 7860caaccactac tcgacttgat
cgagtgcgcc tttggagaaa tatcatccac ccatctacct 7920acgggtactc
gttttaaatt cggggcgatg atgaaatccg gaatgttcct cacacttttt
7980gtcaacacag ttttgaatgt cgttatcgcc agcagagtac tagaagagcg
gcttaaaacg 8040tccagatgtg cagcgttcat tggcgacgac aacatcatac
atggagtagt atctgacaaa 8100gaaatggctg agaggtgcgc cacctggctc
aacatggagg ttaagatcat cgacgcagtc 8160atcggtgaga gaccacctta
cttctgcggc ggatttatct tgcaagattc ggttacttcc 8220acagcgtgcc
gcgtggcgga tcccctgaaa aggctgttta agttgggtaa accgctccca
8280gccgacgacg agcaagacga agacagaaga cgcgctctgc tagatgaaac
aaaggcgtgg 8340tttagagtag gtataacagg cactttagca gtggccgtga
cgacccggta tgaggtagac 8400aatattacac ctgtcctact ggcattgaga
acttttgccc agagcaaaag agcattccaa 8460gccatcagag gggaaataaa
gcatctctac ggtggtccta aatagtcagc atagtacatt 8520tcatctgact
aatactacaa caccaccacc tctagagctt gccgccacca tggtgagcaa
8580gggcgaggag ctgttcaccg gggtggtgcc catcctggtc gagctggacg
gcgacgtgaa 8640cggccacaag ttcagcgtgt ccggcgaggg cgagggcgat
gccacctacg gcaagctgac 8700cctgaagttc atctgcacca ccggcaagct
gcccgtgccc tggcccaccc tcgtgaccac 8760cctgacctac ggcgtgcagt
gcttcagccg ctaccccgac cacatgaagc agcacgactt 8820cttcaagtcc
gccatgcccg aaggctacgt ccaggagcgc accatcttct tcaaggacga
8880cggcaactac aagacccgcg ccgaggtgaa gttcgagggc gacaccctgg
tgaaccgcat 8940cgagctgaag ggcatcgact tcaaggagga cggcaacatc
ctggggcaca agctggagta 9000caactacaac agccacaacg tctatatcat
ggccgacaag cagaagaacg gcatcaaggt 9060gaacttcaag atccgccaca
acatcgagga cggcagcgtg cagctcgccg accactacca 9120gcagaacacc
cccatcggcg acggccccgt gctgctgccc gacaaccact acctgagcac
9180ccagtccgcc ctgagcaaag accccaacga gaagcgcgat cacatggtcc
tgctggagtt 9240cgtgaccgcc gccgggatca ctcacggcat ggacgagctg
tacaagtaaa gcggccgtga 9300gcatgcaggc cttgggccca atgatccgac
cagcaaaact cgatgtactt ccgaggaact 9360gatgtgcata atgcatcagg
ctggtacatt agatccccgc ttaccgcggg caatatagca 9420acactaaaaa
ctcgatgtac ttccgaggaa gcgcagtgca taatgctgcg cagtgttgcc
9480acataaccac tatattaacc atttatctag cggacgccaa aaactcaatg
tatttctgag 9540gaagcgtggt gcataatgcc acgcagcgtc tgcataactt
ttattatttc ttttattaat 9600caacaaaatt ttgtttttaa catttcaaaa
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 9660aaagggaatt cctcgattaa
ttaagcggcc gctcgagatg gcacacgtgt tacggtttta 9720ccgtcgacct
ctagctagag cttggcgtaa tcatggtcat agctgtttcc tgtgtgaaat
9780tgttatccgc tcacaattcc acacaacata cgagccggaa gcataaagtg
taaagcctgg 9840ggtgcctaat gagtgagcta actcacatta attgcgttgc
gctcactgcc cgctttccag 9900tcgggaaacc tgtcgtgcca gctgcattaa
tgaatcggcc aacgcgcggg gagaggcggt 9960ttgcgtattg ggcgctcttc
cgcttcctcg ctcactgact cgctgcgctc ggtcgttcgg 10020ctgcggcgag
cggtatcagc tcactcaaag gcggtaatac ggttatccac agaatcaggg
10080gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa
ccgtaaaaag 10140gccgcgttgc tggcgttttt ccataggctc cgcccccctg
acgagcatca caaaaatcga 10200cgctcaagtc agaggtggcg aaacccgaca
ggactataaa gataccaggc gtttccccct 10260ggaagctccc tcgtgcgctc
tcctgttccg accctgccgc ttaccggata cctgtccgcc 10320tttctccctt
cgggaagcgt ggcgctttct catagctcac gctgtaggta tctcagttcg
10380gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac cccccgttca
gcccgaccgc 10440tgcgccttat ccggtaacta tcgtcttgag tccaacccgg
taagacacga cttatcgcca 10500ctggcagcag ccactggtaa caggattagc
agagcgaggt atgtaggcgg tgctacagag 10560ttcttgaagt ggtggcctaa
ctacggctac actagaagaa cagtatttgg tatctgcgct 10620ctgctgaagc
cagttacctt cggaaaaaga gttggtagct cttgatccgg caaacaaacc
10680accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag
aaaaaaagga 10740tctcaagaag atcctttgat cttttctacg gggtctgacg
ctcagtggaa cgaaaactca 10800cgttaaggga ttttggtcat gagattatca
aaaaggatct tcacctagat ccttttaaat 10860taaaaatgaa gttttaaatc
aatctaaagt atatatgagt aaacttggtc tgacagttac 10920caatgcttaa
tcagtgaggc acctatctca gcgatctgtc tatttcgttc atccatagtt
10980gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc
tggccccagt 11040gctgcaatga taccgcgaga cccacgctca ccggctccag
atttatcagc aataaaccag 11100ccagccggaa gggccgagcg cagaagtggt
cctgcaactt tatccgcctc catccagtct 11160attaattgtt gccgggaagc
tagagtaagt agttcgccag ttaatagttt gcgcaacgtt 11220gttgccattg
ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc ttcattcagc
11280tccggttccc aacgatcaag gcgagttaca tgatccccca tgttgtgcaa
aaaagcggtt 11340agctccttcg gtcctccgat cgttgtcaga agtaagttgg
ccgcagtgtt atcactcatg 11400gttatggcag cactgcataa ttctcttact
gtcatgccat ccgtaagatg cttttctgtg 11460actggtgagt actcaaccaa
gtcattctga gaatagtgta tgcggcgacc gagttgctct 11520tgcccggcgt
caatacggga taataccgcg ccacatagca gaactttaaa agtgctcatc
11580attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt
gagatccagt 11640tcgatgtaac ccactcgtgc acccaactga tcttcagcat
cttttacttt caccagcgtt 11700tctgggtgag caaaaacagg aaggcaaaat
gccgcaaaaa agggaataag ggcgacacgg 11760aaatgttgaa tactcatact
cttccttttt caatattatt gaagcattta tcagggttat 11820tgtctcatga
gcggatacat atttgaatgt atttagaaaa ataaacaaat aggggttccg
11880cgcacatttc cccgaaaagt gccacctgac gtc 11913
* * * * *